A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
Phase: NA
Conditions: Endometrial Cancer, Uterine Cancer, Cervical Cancer
Sponsor: Novadaq Technologies ULC, now a part of Stryker

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Clinical Study Protocol 
PROTOCOL NUMBER 
PP LNM 01 
TITLE 
A Randomized, Prospective, Open Label, Multicenter Study 
Assessing the Safety and Utility of PINPOINT® Near Infrared 
Fluorescence Imaging in the Identification of Lymph Nodes in 
Subjects with Uterine and Cervical Malignancies who are 
Undergoing Lymph Node Mapping 
SHORT TITLE 
FILM 
PROTOCOL VERSION 
Version 6.0, August 25th, 2017 
SPONSOR 
Novadaq Technologies Inc. 
5090 Explorer Dr., Ste. 
202, Mississauga, Ontario, 
Canada, L4W 4T9 
Confidential 
This is a Novadaq Technologies Inc., document that contains confidential information. It is intended solely 
for the recipient clinical investigator(s) and must not be disclosed to any other party. 
Page 1 of 56 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 3 of 56 
Novadaq - CONFIDENTIAL 
PROTOCOL APPROVAL 
Protocol Number: 
PP LNM 01 
Title of Protocol: 
A Randomized, Prospective, Open Label, Multicenter Study Assessing the 
Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the 
Identification of Lymph Nodes in Subjects with Uterine and Cervical 
Malignancies who are Undergoing Lymph Node Mapping. 
Version: 
6.0, August 25th, 2017 
Approved by: 
Lori Swalm 
Sr. Vice President, Regulatory, 
Clinical and Economic Affairs 
Novadaq Technologies Inc. 
Date 
Approved by: 
Matt McKittrick On behalf of 
Yohan D’Souza, PhD Clinical 
Regulatory Scientist Novadaq 
Technologies Inc. 
Date 
08/25/2017

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 3 of 56 
Novadaq - CONFIDENTIAL 
PROTOCOL APPROVAL 
Protocol Number: 
PP LNM 01 
Title of Protocol: 
A Randomized, Prospective, Open Label, Multicenter Study Assessing the 
Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the 
Identification of Lymph Nodes in Subjects with Uterine and Cervical 
Malignancies who are Undergoing Lymph Node Mapping. 
Version: 
6.0, August 25th, 2017 
Approved by: 
Lori Swalm 
Sr. Vice President, Regulatory, 
Clinical and Economic Affairs 
Novadaq Technologies Inc. 
Date 
Approved by: 
Matt McKittrick On behalf of 
Yohan D’Souza, PhD Clinical 
Regulatory Scientist Novadaq 
Technologies Inc. 
Date 
8/25/17

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 5 of 56 
Novadaq - CONFIDENTIAL 
PROTOCOL SUMMARY 
Study Number and Title: 
PP LNM 01: A Randomized, Prospective, Open Label Multicenter Study Assessing the Safety and Utility 
of PINPOINT® Endoscopic Fluorescence Imaging to Identify Lymph Nodes in Patients with Uterine and 
Cervical Malignancies who are Undergoing Lymph Node Mapping. 
Clinical Phase: Pivotal / Investigational Device Study 
Study Objectives: 
Primary: 
To assess the effectiveness of intraoperative PINPOINT Near-Infrared Fluorescence imaging in the 
identification of lymph nodes in subjects with uterine and cervical malignancies who are undergoing 
lymph node mapping. 
Secondary: 

To evaluate the effectiveness of PINPOINT and Blue dye in the identification of at least one
lymph node (confirmed to be lymphoid tissue) per subject.

To assess the safety of interstitial injection of ICG for intraoperative lymphatic mapping.
Study Design: 
This is a randomized prospective, open label, multicenter study to assess the safety and effectiveness 
of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in 
subjects with uterine and cervical malignancies who are undergoing LN mapping. This is a non-inferiority 
within-patient comparison study to determine the effectiveness of PINPOINT in the identification of LNs 
compared to LNs identified with Blue dye (1% Isosulfan blue). Approximately 150 subjects will be 
enrolled at up to 10 centers in North America. Prior to enrolling study subjects, participating surgeons 
at each center will be trained to perform intraoperative identification and mapping of LNs with IC2000 
and Blue dye. Participating surgeons will be required to have completed at least 10 LN mapping 
procedures with a minimum of 3 LN mapping cases performed with PINPOINT prior to the initiation of 
enrollment. 
Screening: 
Subjects diagnosed with International Federation of Gynecology and Obstetrics (FIGO) clinical stage I 
endometrial or cervical cancer scheduled for surgery that includes clinically indicated LN mapping will 
be evaluated at baseline to determine if they meet the inclusion/exclusion criteria of the protocol. 
Subjects will be assessed to determine overall health status including demographics, vital signs, 
diagnosis and relevant medical history/underlying conditions. Eligible subjects who provide informed 
consent will be considered for inclusion into the study. 
Day 0: 
On the day of surgery subjects will be randomized (1:1) to either the Blue-PINPOINT (B-P) Arm or the 
PINPOINT-BLUE (P-B) Arm. Subjects in each arm will be randomized according to an independently 
generated randomization scheme to undergo lymphatic mapping with Blue dye first followed by mapping 
with PINPOINT (B-P Arm) or to undergo lymphatic mapping with PINPOINT first followed by mapping 
with Blue dye (P-B Arm). 
Minimally invasive surgery will be performed according to the surgeon’s standard practice. 
The cervix will be injected four (4) times with a 1 ml solution Blue dye (1% solution: 10mg/ml) for a total 
dose of 40 mg and four (4) times with 1 ml of a 1.25 mg/ml solution of IC2000 for a total dose of 5 mg. 
The injection of Blue dye and IC2000 will occur while the subject is under anesthesia in the operating 
room. . 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 6 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
In order to minimize the spillage of Blue dye or IC2000 interfering with the mapping procedure when 
LNs are excised, mapping will be performed on one side of the pelvis followed by other side and 
mapping with both Blue dye and PINPOINT will be performed prior to the excision of any LNs. 
Subjects randomized into the B-P Arm will be administered Blue dye first followed by the administration 
of IC2000 and undergo LN mapping with Blue dye first followed by mapping with PINPOINT. LN 
mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines 
that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT 
until all ‘IC2000’ nodes are identified or the investigator determines that ‘IC2000’ nodes cannot be 
identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, all 
LNs identified with Blue dye or PINPOINT will be excised. 
Subjects randomized into the P-B Arm will be administered IC2000 first followed by the administration 
of Blue dye and undergo LN mapping with PINPOINT first followed by mapping with Blue dye. LN 
mapping with PINPOINT will be performed until the investigator identifies all ‘IC2000’ nodes or 
determines that ‘IC2000’ nodes cannot be identified. Once complete, the Investigator will begin mapping 
with Blue dye until all ‘blue’ nodes are identified or the investigator determines that ‘blue’ nodes cannot 
be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, 
LNs identified with Blue dye or PINPOINT will be excised. 
Bilateral LN mapping for Clinical Stage I endometrial cancer will be performed according to the NCCN 
Guidelines for Uterine Neoplasms, SLN Algorithm for Surgical Staging of Endometrial Cancer; and LN 
mapping for Clinical Stage I cervical cancer will be performed according to the NCCN Guidelines for 
Cervical Neoplasms, Surgical/SLN Mapping Algorithm for Early-Stage Cervical Cancer1,2. 
The surgeon will identify LN and lymphatic vessels based on visualization with white light for blue dye 
or PINPOINT for IC2000. 
LN Mapping with PINPOINT: 
Intraoperative identification of LNs with IC2000 will be based on the following criteria: 
 
Direct visual identification of a node by NIR fluorescence with IC2000 using PINPOINT. 
 
Visibly or palpably abnormal lymph nodes designated as palpable masses and excised 
regardless of visible fluorescence. 
Mapping will be considered complete when all nodes meeting any of the criteria above are identified 
and documented and the surgeon has scanned the full 360-degree area within the abdominal cavity. 
Fluorescent ducts should be followed in both directions in order to identify LNs to be excised. 
LN Mapping with Blue dye: 
Intraoperative identification of LNs with Blue dye will be based on the following criteria: 
 
Direct visual identification of a node stained with Blue dye. 
 
Visibly or palpably abnormal lymph nodes designated as palpable masses and excised 
regardless of visible blue dye. 
Mapping will be considered complete when all nodes meeting any of the criteria above are identified 
and documented and the surgeon has scanned the full 360-degree area within the abdominal cavity 
Blue ducts should be followed in both directions in order to identify LNs to be excised. 
Classification of LNs: 
All LNs identified will be classified as: 
1. Fluorescent only 
2. Blue only 
3. Both (Fluorescent and blue) 
4. Abnormal or palpably hard (non-stained) 
5. Non-stained node found at origin or termination of fluorescent duct 
6. Non-stained node found at origin or termination of blue duct 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 7 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
7.   Non-stained node found at origin or termination of fluorescent and blue duct 
Effectiveness of intraoperative Blue dye in identifying LNs will be based on the proportion of LNs 
identified by visualization under white light and confirmed as lymphoid tissue by histology divided by the 
total number of LNs identified and excised. 
Effectiveness of intraoperative PINPOINT in identifying LNs will be based on the proportion of LNs 
identified by PINPOINT and confirmed as lymphoid tissue by histology divided by the total number of 
LNs identified and excised. 
Details of the surgery, including intraoperative findings will be documented. Surgical data will be 
collected including the ability to identify LNs the number of LNs identified and removed, the ability to 
unilaterally and bilaterally map LNs, and the anatomical location and distribution of identified LNs. Failed 
mapping is defined as no LNs detected. 
Follow-up and Post-operative Complications: 
Subjects will have standard of care assessments throughout the study according to the 
hospital/institution’s standard procedures as well as study specific visits to monitor occurrence of any 
adverse events/ adverse device effects on the date of discharge and Day 30 (±7 days). 
Study Population 
To be eligible for the study, subjects must meet the following main inclusion criteria: 
• 18 years of age or older 
• Subjects with FIGO Clinical Stage I endometrial cancer undergoing minimally invasive hysterectomy 
with lymph node mapping. 
• Subjects with FIGO Clinical Stage IA cervical cancer ≤ 2 cm in size undergoing minimally invasive 
hysterectomy, trachelectomy, or conization with lymph node mapping. Subjects with clinical Stage 
IA1 cervical cancer without lympho vascular space involvement (LVSI) and negative margins on cone 
biopsy are not to be included. 
• Subjects with negative nodal status (N0) 
• Subjects with negative metastatic involvement (M0). 
Subjects meeting any of the following criteria will be excluded from the study: 
• Have had prior dissection and/or radiation in pelvis. 
• Advanced cervical or endometrial cancer, T3/T4 lesions 
• Diagnosis of cervical cancer with a tumor size greater than 2 cm. 
• Locally advanced or inflammatory cervical or uterine cancer 
• Metastatic cervical or uterine cancer. 
• Known allergy or history of adverse reaction to ICG, iodine or iodine dyes. 
• Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane. 
• Hepatic dysfunction defined as MELD Score > 12. 
• Renal dysfunction defined as serum creatinine ≥ 2.0 mg/dl. 
• Subjects who have participated in another investigational study within 30 days prior to surgery. 
• Pregnant or lactating subjects. 
• Subjects who, in the Investigator's opinion, have any medical condition that makes the subject a poor 
candidate for the investigational procedure, or interferes with the interpretation of study results. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 8 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
Study Devices and Imaging Agents: 
PINPOINT® Endoscopic Fluorescence Imaging System 
An endoscopic fluorescence imaging system for high definition (HD) visible (VIS) light and near infrared 
(NIR) fluorescence imaging that includes the following components: 
• A surgical endoscope optimized for VIS/NIR illumination and imaging. 
• A camera head that is also optimized for VIS/NIR imaging and mounts to the endoscope eyepiece 
• A flexible light guide cable. 
• An endoscopic Video Processor/Illuminator for VIS/NIR illumination to the surgical endoscope via a 
flexible light guide cable, and the image processing required to generate simultaneous, real-time HD 
video color and NIR fluorescence images. 
• A high-definition medical video recorder that allows the capture of still images and video. 
• The PINPOINT kit containing the imaging agent and aqueous solvent. 
The imaging agent used with PINPOINT is ICG, which is a sterile, water-soluble tricarbocyanine dye 
with a peak spectral absorption at 800-810 nm in blood plasma or blood. ICG contains not more than 
5.0% sodium iodide. In this study, investigational ICG, IC2000, will be administered to subjects. 
Isosufan Blue 1% (Mylan) is a water-soluble contrast dye and is administered as a 1% solution for the 
purposes of lymphography. 
Study Variables: 
Primary Variables 
Effectiveness of intraoperative PINPOINT and Blue dye in identifying LNs defined as the proportion of 
LNs identified by PINPOINT and Blue dye respectively (confirmed as lymphoid tissue by histology) 
divided by the total number of LNs identified and excised. 
Secondary Variables 
LN detection rate with PINPOINT or Blue dye, defined as the proportion of cases in which at least one 
LN is identified with PINPOINT or Blue dye (confirmed as lymphoid tissue by histology). 
Incidence of adverse events and adverse device events/effects of PINPOINT and Blue dye. 
Other Variables 
• Bilateral LN detection rate defined as the proportion of cases in which at least one LN is identified on 
right and left side of the pelvis. 
• Proportion of LNs identified from following LCs. 
• Anatomic distribution of LNs. 
. 
Study Procedures and Assessments: 
The following tests and procedures will be performed: 
• Vital signs, height, weight, demographics, surgical predictive factors. 
• Relevant medical history and underlying conditions. 
• Assessment of eligibility criteria. 
• Randomization to the B-P Arm or P-B Arm. 
• Imaging agent administration 
• LN identification with PINPOINT and Blue dye followed by excision of all LNs. 
• Documentation of LN mapping procedure. 
• Histological assessment of all excised lymph nodes 
• Concomitant medications 
• Assessment of surgical complications 
• Adverse events and adverse device effects 
• Follow-up visits on date of discharge, and Day 30. Subjects with a discharge date later than Day 30 
will have their last study visit on Day 30. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 9 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
Sample Size and Statistical Analysis: 
The FILM trial is a non-inferiority study comparing lymph node detection rates between Blue dye and 
PINPOINT. A sample size of approximately 150 evaluable subjects (to identify 525 LNs) is required to 
show the LN detection rate for PINPOINT is non-inferior to that with Blue dye with 80% power and a 5% 
2-sided significance level with a 5% non-inferiority margin. 
Both a modified Intent-to-Treat (mITT) and Per-Protocol (PP) analysis population will be utilized for the 
primary analysis. Analysis of the primary objective will be conducted using a 2-sided 95% confidence 
interval for the difference in proportions. A a non-inferiority test will be conducted using the PP and the 
mITT analysis populations.  If and only if non-inferiority is claimed, a superiority test will be conducted 
using the mITT analysis population.3  As a supporting analysis of the primary outcome, the analysis will 
also be repated using the as-treated (AT) population.  The secondary objectives will be tested using a 
two -sided 5% significance level with a step-down multiplicity adjustment. 
Study Duration: 
The study is expected to begin in 2015 and complete enrollment in 18 months. Therefore, the study is 
expected to complete in 2017. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 10 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
 
 
TABLE OF CONTENTS 
PROTOCOL APPROVAL ..................................................................................................... 2 
PROTOCOL APPROVAL ..................................................................................................... 3 
PROTOCOL APPROVAL ..................................................................................................... 4 
PROTOCOL SUMMARY ...................................................................................................... 5 
ABBREVIATIONS AND DEFINITIONS .............................................................................. 13 
1 
INTRODUCTION AND BACKGROUND .................................................................. 14 
1.1 
Background ........................................................................................................... 14 
1.1.1 Lymph Node Identification and Mapping ..................................................................... 14 
1.1.2 Endometrial and Cervical Cancer ............................................................................... 14 
1.1.3 Summary of Clinical Data for NIR Fluorescence Imaging with ICG for Lymphatic 
Mapping ................................................................................................................. 15 
1.1.4 Clinical Studies........................................................................................................... 15 
1.2 
Potential Risks and Benefits to Human Subjects ................................................ 18 
2 
STUDY OBJECTIVES ............................................................................................. 19 
2.1 
Objectives .............................................................................................................. 19 
2.1.1 Primary Objectives ..................................................................................................... 19 
2.1.2 Secondary Objectives ................................................................................................ 19 
3 
INVESTIGATIONAL PLAN ..................................................................................... 19 
3.1 
Study Design Overview ......................................................................................... 19 
4 
SELECTION AND WITHDRAWAL OF SUBJECTS ................................................ 22 
4.1 
Number of Subjects ............................................................................................... 22 
4.2 
Inclusion Criteria ................................................................................................... 22 
4.3 
Exclusion Criteria .................................................................................................. 23 
4.4 
Withdrawal of Subjects ......................................................................................... 23 
5 
RANDOMIZATION, BLINDING AND SUBJECT IDENTIFICATION 
PROCEDURES ....................................................................................................... 24 
5.1 
Randomization ....................................................................................................... 24 
5.1.1 Randomization Procedure .......................................................................................... 24 
5.2 
Subject Identification ............................................................................................ 25 
6 
STUDY TREATMENTS ........................................................................................... 25 
6.1 
Device Description ................................................................................................ 25 
6.2 
Imaging Agent Description ................................................................................... 26 
6.2.1 Indocyanine Green IC2000....................................................................................... 26 
6.2.1.1 
Overview and Pharmacokinetics of Investigational Product .............................. 27 
6.2.1.2 
Description of Investigational Product (IC2000) ................................................ 27 
6.2.1.3 
Chemistry and Manufacturing ........................................................................... 27 
6.2.1.4 
Labelling of IC2000 for Injection ....................................................................... 28 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 11 of 56 
Novadaq - CONFIDENTIAL 
 
 
6.2.1.5 
Packaging and Distribution of IC2000 .............................................................. 28 
6.2.1.6 
Storage and administration of IC2000 for Injection ........................................... 28 
6.2.2 Blue Dye (Isosulfan Blue) ........................................................................................ 29 
6.2.2.1 
Storage and administration ............................................................................... 29 
6.3 
Concomitant Treatment ........................................................................................ 29 
7 
RISKS/PRECAUTIONS .......................................................................................... 30 
7.1 
PINPOINT System – Endoscopes, Camera and Video Processor Illuminator 
Unit ........................................................................................................................ 30 
7.2 
Indocyanine Green (IC2000) .................................................................................. 30 
7.3 
Isosulfan Blue (Blue Dye)......................................................................................... 31 
8 
STUDY PROCEDURES .......................................................................................... 32 
8.1 
Schedule of Events ............................................................................................... 32 
8.2 
Baseline/Screening Procedures (Day -30 to Day 0) ............................................. 33 
8.3 
Day 0 Procedures .................................................................................................. 33 
8.3.1 Lymph Node Mapping Procedure ............................................................................... 34 
8.3.1.1 
Imaging Agent Dosing and Administration of Blue dye ..................................... 35 
8.3.1.2 
Imaging Agent Dosing and Administration of IC2000 ........................................ 35 
8.3.1.3 
Identification of Lymph Nodes with Blue Dye .................................................... 36 
8.3.1.4 
Identification of Lymph Nodes with PINPOINT ................................................. 36 
8.4 
Post-operative Follow-up Visits (Day of discharge to Day 30) ........................... 38 
8.5 
Histopathology of Excised LN .............................................................................. 38 
9 
EVALUATION, RECORDING, AND REPORTING OF ADVERSE EVENTS ........... 39 
9.1 
Definitions .............................................................................................................. 39 
9.1.1 Adverse Event (AE) .................................................................................................... 39 
9.1.2 Adverse Device Effect (ADE) ..................................................................................... 40 
9.1.3 Serious Adverse Event (SAE) .................................................................................... 40 
9.1.4 Unanticipated Adverse Device Effect (UADE) ............................................................ 40 
9.2 
Adverse Event Descriptions ................................................................................. 40 
9.2.1 Intensity ..................................................................................................................... 40 
9.2.2 Relationship ............................................................................................................... 41 
9.3 
Reporting and Evaluation of Serious Adverse Events and Unanticipated 
Adverse Device Effects  ....................................................................................... 41 
9.4 
Follow-up for Adverse Device Effects and Adverse Events ............................... 41 
9.5 
Reporting of Technical Complaints/Device Deficiencies .................................... 42 
9.5.1 Definitions .................................................................................................................. 42 
9.5.2 Reporting Procedures ................................................................................................ 42 
9.6 
ADEs Technical Complaints/Device Deficiencies that are UADEs ..................... 42 
10 
STATISTICAL CONSIDERATIONS ........................................................................ 43 
10.1 
Primary Objective .................................................................................................. 43 
10.2 
Hypotheses ............................................................................................................ 43 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 12 of 56 
Novadaq - CONFIDENTIAL 
 
 
10.3 
Statistical Analysis ................................................................................................ 43 
10.4 
Sample Size Considerations ................................................................................. 44 
10.5 
Data Sets to be Analyzed ...................................................................................... 45 
10.5.1 Per-protocol (PP) .................................................................................................... 45 
10.5.2 Modified Intent to treat (mITT) ............................................................................... 45 
10.5.3 As Treated (AT) ...................................................................................................... 45 
10.5.4 Safety (S) ................................................................................................................ 45 
10.6 
Secondary Objectives ........................................................................................... 46 
10.6.1 Demographic and Baseline Data ........................................................................... 47 
10.6.2 Safety Variables and Analysis ............................................................................... 47 
10.7 
Handling of Missing Data ...................................................................................... 48 
10.8 
Pooling of Site Data ............................................................................................... 48 
11 
ESTIMATED DURATION OF THE STUDY ............................................................. 48 
12 
STUDY ETHICAL CONSIDERATIONS ................................................................... 48 
12.1 
Ethical Conduct of the Study ................................................................................ 48 
12.2 
Informed Consent .................................................................................................. 48 
12.3 
Institutional Review Board, Ethics Committee, or Research Ethics Board 
(IRB) ....................................................................................................................... 49 
12.4 
Data and Safety Monitoring Board ....................................................................... 49 
13 
ADMINISTRATIVE PROCEDURES ........................................................................ 49 
13.1 
Sponsor's Responsibilities ................................................................................... 49 
13.1.1 Public Disclosure of Clinical Trials ............................................................................ 49 
13.1.2 Study Supplies ......................................................................................................... 49 
13.1.3 Investigator Training ................................................................................................. 49 
13.1.3.1 
Study Initiation Visit .......................................................................................... 49 
13.1.3.2 
PINPOINT System ........................................................................................... 50 
13.1.4 Ongoing Communication of Safety Information During the Study ............................. 50 
13.1.5 Study Monitoring ...................................................................................................... 50 
13.1.6 Records Retention ................................................................................................... 50 
13.2 
Investigator's Responsibilities ............................................................................. 50 
13.2.1 Reporting and Recording of Study Data ................................................................... 50 
13.2.2 Source Documentation ............................................................................................. 50 
13.2.3 Study Devices and Imaging Agents .......................................................................... 51 
13.2.4 Records Retention ................................................................................................... 51 
14 
DATA MANAGEMENT ............................................................................................ 51 
15 
POLICY FOR PUBLICATION AND PRESENTATION OF DATA ............................ 53 
16 
REFERENCES ........................................................................................................ 54 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 13 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
ABBREVIATIONS AND DEFINITIONS 
 
ADE 
Adverse device effect 
AE 
Adverse event 
AT 
As-treated 
B-P 
BLUE-PINPOINT 
CFR 
Code of Federal Regulations 
CRF 
Case Report Form 
CSF 
Color Segmented Fluorescence 
CT 
Computerized Tomography 
DSMB 
Data and Safety Monitoring Board 
EC 
Ethics Committee 
FIGO 
International Federation of Gynecology and Obstetrics 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
GMP 
Good Manufacturing Practice 
H&E 
Hematoxylin and eosin 
HD 
High Definition 
HAS 
Human serum albumin 
IA 
Imaging agent 
ICH 
International Conference on Harmonization 
ICG 
Indocyanine Green 
IRB 
Institutional Review Board 
IRC 
Image Review Committee 
IV 
Intravenous 
LC 
Lymphatic channel 
LN 
Lymph node 
MELD 
Model for end-stage liver disease 
mITT 
Modified intent-to-treat 
NCCN 
National Comprehensive Cancer Network 
NDA 
New drug application 
NIR 
Near-Infrared 
P-B 
PINPOINT-BLUE 
PINPOINT 
PINPOINT Endoscopic Fluorescence Imaging System 
PP 
Per-Protocol 
REDCap 
Research Electronic Data Capture 
SADE 
Serious Adverse Device Effect 
SAE 
Serious Adverse Event 
SLN 
Sentinel lymph node 
US 
United States 
UADE 
Unanticipated Adverse Device Effect 
VIS 
Visible 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 14 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
1 INTRODUCTION AND BACKGROUND 
 
The study will be conducted in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and in compliance with the protocol, Good Clinical Practice (GCP) and 
all applicable regulations. 
 
1.1 Background 
 
The purpose of this study is to assess the effectiveness of intraoperative PINPOINT Near 
Infrared Fluorescence Imaging in identification of lymph nodes (LN) in subjects with uterine and 
cervical malignancies who are undergoing lymph node mapping and to investigate the safety of 
interstitial injection of indocyanine green (IC2000) dye for intraoperative lymphatic mapping 
using PINPOINT Near Infrared Fluorescence Imaging. 
 
1.1.1 Lymph Node Identification and Mapping 
 
Identification of the tumor draining lymph nodes (LN has become an important step for staging 
cancers that spread through the lymphatic system. LN mapping involves the use of dyes and/or 
radiotracers to identify the LNs either for biopsy or resection and subsequent pathological 
assessment for metastasis. The goal of lymphadenectomy at the time of surgical staging is to 
identify and remove the LNs that are at high risk for local spread of the cancer 
 
LN identification can be accomplished using several different methods, with the basic technique 
involving the injection of a tracer that identifies the lymphatic drainage pathway from the primary 
tumor6. The tracers used may be colored dyes (e.g. Isosulfan blue), or radioisotopes (e.g. 
technetium-99m) for intraoperative localization with a gamma probe; or, a combination of both. 
Recently, ICG using near-infrared (NIR) fluorescence imaging for visualization has emerged as 
a potentially effective method for several cancers including breast, skin (melanoma), cervical, 
endometrial, lung and gastrointestinal7. 
 
The PINPOINT system is an endoscopic NIR fluorescence imaging system used during 
minimally invasive surgical procedures. PINPOINT acquires NIR fluorescence images of an 
imaging agent (ICG) to allow for direct real time visual identification of a lymph node and/or the 
afferent lymphatic channel intraoperatively. ICG is a commonly used water soluble intravascular 
dye approved for human use in the United States and Canada. It has a peak spectral absorption 
at approximately 800 nm and can be used as a lymphatic NIR fluorophore. ICG binds primarily 
to globulins and to a lesser extent to lipoproteins and albumin8. In general, when injected 
interstitially, the protein binding properties of ICG cause it to be rapidly taken up by the lymph 
and moved through the conducting vessels to the LN9. The NIR fluorescent positive lymph nodes 
are represented on the PINPOINT screen in PINPOINT (green pseudo-color superimposed on 
white light image), SPY (black and white) or SPY CSF (color segmented fluorescence) mode. 
 
1.1.2 Endometrial and Cervical Cancer 
 
Endometrial cancer is the most common gynecological cancer, and it is estimated that 52,630 
new cases will be diagnosed in the United States (US)10 and 6,000 new cases will be diagnosed 
in Canada in 201411. Cervical cancer affects a lower number of women with 12,36012 and 1,45011  
new cases estimated in the US and Canada respectively for 2014. The most important 
prognostic factor for subjects is accurate surgical staging, as lymph node status is a predictor 
of outcome and may influence treatment following surgery. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 15 of 56 
Novadaq - CONFIDENTIAL 
 
 
Identification of LNs and LN mapping for endometrial cancer is being evaluated as a method for 
surgical staging to be used in subjects with uterine confined tumors when there is no metastasis 
demonstrated by imaging studies and no obvious extrauterine disease13. The current standard 
of care is to perform a complete or selective para-aortic lymphadenectomy for staging (FIGO) 
which can lead to morbidities such as lower extremity lymphedema and lymphocyst 
formation4.Although the inclusion of pelvic and para-aortic lymphadenectomy in the surgical 
management is part of the FIGO staging, it remains controversial. Therefore, the decision about 
the extent of lymphadenectomy (e.g. pelvic nodes only or both pelvic and para-aortic nodes) 
done by the surgeon can still be based on the preoperative and intraoperative findings. 
 
 
1.1.3 Summary of Clinical Data for NIR Fluorescence Imaging with ICG for Lymphatic Mapping 
 
The imaging agent (IA), ICG (indocyanine green for injection, USP) 25 mg for Injection in the form 
of a sterile lyophilized powder containing indocyanine green with no more than 5% sodium iodide 
is approved by the FDA for determining cardiac output, hepatic function and liver blood flow, and 
for ophthalmic angiography via intravascular administration14,15. ICG is also approved under a 
510(k) by the FDA for assessing blood flow and tissue perfusion in a variety of surgical and non- 
surgical procedures16. ICG can be administered intravenously or intra-arterially. It absorbs light 
in the near-infrared region at 806 nm, and emits fluorescence (light) at a slightly longer 
wavelength, 830 nm. When injected intravenously, ICG rapidly and extensively binds to plasma 
proteins and is confined to the intravascular compartment with minimal leakage into the 
interstitium. This property makes ICG an ideal agent for the acquisition of high quality images of 
lymph nodes and lymphatic vessels (i.e., for NIR fluorescence lymphography). 
 
1.1.4 Clinical Studies 
 
The Sponsor has not conducted any clinical trials on the use of intraoperative PINPOINT Near 
Infrared Fluorescence Imaging with ICG in identification and mapping of LN to date. However, 
12 studies with performance and/or safety data using the Sponsor’s fluorescence imaging 
devices or those with equivalent characteristics have been reported in the literature on the use 
of ICG in lymphatic mapping of gynecological cancers (Table 1). 
 
 
TABLE 1. Lymphatic Mapping Studies in Gynecological Cancers 
 
 
Author 
Indication 
Device 
Summary 
Furukawa et 
al., 201017 
Cervical 
PDE 
ICG fluorescence imaging was used to identify SLN during sentinel node 
navigation surgery in cervical cancer patients. No allergic reactions to ICG 
were observed. 
Crane et al., 
201118 
Cervical 
Prototype 
multispectral 
fluorescence 
camera system 
Intraoperative lymphatic mapping and SLN detection was carried out in 
cervical cancer patients using ICG fluorescence imaging and patent blue 
dye. No side effects were noted after injection of ICG or patent blue dye. 
Crane et al., 
201119 
Vulvar 
Prototype 
multispectral 
fluorescence 
camera system 
Intraoperative transcutaneous lymphatic mapping was carried out in vulvar 
cancer patients in a comparison using ICG fluorescence imaging, 99m- 
Technetium-nanocolloid and patent blue dye. No side effects related to 
ICG injection were noted. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 16 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
Author 
Indication 
Device 
Summary 
Holloway et 
al., 201220 
Endometria 
l 
da Vinci Surgical 
System 
Retrospective comparison of results from lymphatic mapping of pelvic SLN 
using fluorescence NIR imaging of ICG and colorimetric imaging of 
Isosulfan blue dyes in women with endometrial cancer undergoing robotic- 
assisted lymphadenectomy. 
Rossi et al 
201221 
Endometria 
l 
da Vinci Surgical 
System 
Sentinel lymph node (SLN) mapping with indocyanine green (ICG) 
detected by robotic near infrared (NIR) imaging is a feasible technique. 
Schaafsma et 
al 201222 
Cervical 
Mini-FLARE 
Eighteen consecutive early-stage cervical cancer patients scheduled to 
undergo pelvic lymphadenectomy were included. Prior to surgery, 1.6 mL 
of 500 μM ICG:HSA or 500 μM ICG alone was injected transvaginally in 4 
quadrants around the tumor. The Mini-FLARE imaging system was used 
for intraoperative NIR fluorescence detection and quantitation. 
Rossi et al 
201323 
Cervical or 
endometrial 
, Stage 1 
SPY Scope (7 
subjects); da 
Vinci (13 
subjects) 
Robotically assisted endoscopic NIR imaging after injection of ICG was 
used for LN mapping in patients with clinical stage 1 cervical or 
endometrial cancer. No AEs occurred. 
Schaafsma et 
al 201324 
Vulvar 
Mini-FLARE 
NIR fluorescence imaging for SLN biopsy was investigated and ICG vs 
ICG:HSA compared in a double-blind, randomized, non-inferiority trial of 
vulvar cancer patients. The study confirmed the feasibility of NIR 
fluorescence imaging for SLN mapping in vulvar cancer and found no 
advantage in using ICG:HSA over ICG alone. No AEs were associated 
with the use of ICG or ICG:HSA. 
Jewell et al., 
201425 
Endometria 
l and 
cervical 
da Vinci Surgical 
System 
Robotically assisted endoscopic NIR imaging after injection of ICG was 
used for SLN mapping in patients with uterine and cervical malignancies 
Sinno et al. 
201426 
Endometria 
l or CAH 
da Vinci Surgical 
System 
Comparison of NIR fluorometric imaging vs colorimetric imaging for SLN 
mapping in endometrial cancer 
Plante et. al. 
201527 
Endometria 
l and 
cervical 
PINPOINT 
Endoscopic 
System 
Initial experience with PINPOINT Endoscopic NIR imaging for LN 
identification was reported. Study determined PINPOINT/ICG is an 
excellent and safe modality for SLN mapping with a very high (96%) 
detection rate. 
How et. al. 
201528 
Endometria 
l 
da Vinci Surgical 
System 
Comparison of ICG, blue dye and 99mTc-SC mapping in patients 
undergoing robotic-assisted surgery. A mixture of all three modalities is 
feasible and provides good mapping. ICG was found to be superior to blue 
dye and comparable to 99mTc-SC and thus blue dye may not be essential 
for SLN detection. 
 
A total of 550 subjects with early stage gynecological cancers (cervical, endometrial and vulvar) 
have been reported in the literature as having undergone intraoperative SLN mapping with ICG 
fluorescence imaging. Table 2 lists the published studies including the number of subjects 
receiving ICG, the ICG dose, route of administration, SLN detection rate and safety results 
(when reported). All subjects receiving an injection of ICG are listed for studies that included co- 
administration of a colorimetric dye or radiotracer. Of the 12 studies, 7 specifically reported that 
there were no adverse reactions to the procedure. In 4 studies (Crane et al 2011; Furukawa et 
al 2010; Rossi et al, 2011, Plante et al. 2015), ICG fluorescence was used to identify SLNs in 
subjects with cervical or endometrial cancer 17,19,21 Detection rates ranged from 60% to 96%. In 
a study comparing ICG fluorescence and blue dye, Crane et al (2011) found that 89.7% of 
radioactively labelled SLNs in subjects with vulvar cancer could be detected by ICG 
fluorescence compared to 72.4% detected by blue dye18. 
 
Schaafsma et al. compared the use of ICG and ICG conjugated to HSA for NIR fluorescence 
detection of SNs in subjects with early cervical cancer22 and vulvar cancer24. In both studies, no 
difference in SLN detection rates was found between the ICG (6/9; 67% for cervical cancer and 
9/12; 75% for vulvar cancer) and ICG: HSA groups (8/9; 89% for cervical cancer; 10/12; 83% 
for vulvar cancer) (p=0.13, cervical cancer; p=0.27, vulvar cancer). 
 
Jewell et al. completed a retrospective, open label, single center study using NIR fluorescence 
imaging on the robotic platform with intracervical ICG injection for SLN detection in uterine and 
cervical malignancies25. A total of two hundred and twenty-seven cases were performed. When 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 17 of 56 
Novadaq - CONFIDENTIAL 
 
 
ICG alone was used to map cases, 188/197 subjects mapped for a detection rate of 95% 
compared to 93% in cases in which both blue dye and ICG were used. Bilateral mapping was 
seen in 79% of ICG alone cases compared to 77% of cases using ICG and blue dye. The authors 
concluded that NIR fluorescence imaging on the robotic platform has a high bilateral detection 
rate and appears to be favorable to ICG dye alone, with blue dye combined with ICG unnecessary 
for SLN mapping. 
How et al. recently completed a prospective study comparing NIR fluorescence using ICG, blue 
dye and technetium for SLN mapping in endometrial cancer28. A total of 100 subjects underwent 
SLN mapping with a mixture of ICG, blue dye and 99mTc-SC injected directly into the cervix. A 
total of 286 LNs were mapped (2.9 per subject). ICG had a significantly higher detection rate than 
blue dye both in unilateral (87% vs 71%) and bilateral (65% vs 43%) detection rates. The authors 
concluded that mapping with ICG is superior to blue dye and comparable to mapping with 99mTc- 
SC. 
TABLE 2 Lymphatic Mapping Studies in Gynecological Cancers 
 
Author 
Type of 
Cancer 
Number 
of  
Patients 
ICG 
Concentration 
(mg/ml) 
Total Dose of 
ICG (mg) 
Route of 
Administration 
Detection 
Rate 
Safety 
Furukawa 
et al., 2010 
Cervical 
10 
5.00 
1.0 
Cervical 
injectiona 
83% 
No allergic 
reactions 
Crane et 
al., 2011 
Cervical 
(1A1, 1B1, 
IIA) 
10 
0.50 
0.50 
Cervical 
injection 
60% 
No side effects 
reported 
Crane et 
al., 2011 
Vulvar 
10 
0.50 
0.50 
Vulva 
(peritumoral 
injection) 
89.7% 
No side effects 
related to 
intraoperative 
injection of ICG 
Holloway et 
al., 2012b 
Endometria 
l 
35 
1.25 
2.50 
Cervical 
injectiona 
100% 
Not reported 
Rossi et al., 
2012 
Cervical or 
endometrial 
Stage 1 
3 
17 
0.50 
0.50 
0.50, 0.75 & 
1.5 
1.00 
Cervical 
injectiond 
85% 
88% 
No adverse 
events reported 
Rossi et al., 
2012 
Endometria 
l 
12 
17 
0.50 
0.50 
0.50 
1.00 
Hysteroscopic 
endometrial 
Cervical 
Injection 
33% 
 
 
82% 
Not reported 
 
 
Not reported 
Schaafsma 
et al., 2012 
Cervical 
(1B1) 
9 
0.38 
0.62 
Cervicala 
 
67%f 
 
Not reported 
Schaafsma 
et al., 2013 
Vulvar 
12 
0.38 
0.62 
Vulva 
(peritumorally or 
around excision 
scar) 
75% 
No adverse 
reactions 
reported 
Jewell et al. 
2014 
Endometria 
l and 
cervical 
227 
1.25 
2.50 
Cervical 
Injection 
100% 
Not reported 
Sinno et al., 
2014 
Endometria 
l or CAHe 
38 
1.25 
5.00 
Cervical 
injectionc 
78.9% 
Not reported 
Plante et al. 
2015 
Cervical or 
endometrial 
Stage 1 
50 
1.25 
5.00 
Cervical 
Injection 
96% 
No adverse 
events reported 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 18 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
Author 
Type of 
Cancer 
Number 
of  
Patients 
ICG 
Concentration 
(mg/ml) 
Total Dose of 
ICG (mg) 
Route of 
Administration 
Detection 
Rate 
Safety 
How et al. 
2015 
Endometria 
l 
100 
0.25 
0.1 
Cervical 
Injection 
96% 
No adverse 
events reported 
a Injection into 4 quadrants of the cervix (3, 6, 9 and 12 o’clock positions) 
b Retrospective study 
c Injection into cervix at 3 and 9 o’clock positions with 1 cc deep in the stroma and 1 cc submucosally on the right and left of cervix 
for a total volume of 4 ml 
d Injection 1 cm into cervical stroma at 3 and 9 o’clock positions 
e Complex Atypical Hyperplasia 
f Intraoperative bilateral detection rate 
 
 
 
Based on the data available from clinical studies, this Phase III study has been designed to 
demonstrate the effectiveness of intraoperative PINPOINT Near Infrared Fluorescence Imaging 
in lymphatic mapping and to assess the safety of interstitial injection of ICG for intraoperative 
lymphatic mapping. 
 
 
1.2   Potential Risks and Benefits to Human Subjects 
 
Currently the PINPOINT system is classified by the United States Food and Drug Administration 
(FDA) as a Class II medical device with a Product Code of GCJ. PINPOINT for the purposes of 
fluorescence angiography is not identified as a significant risk device on the FDA Information 
Sheet titled "Significant Risk and Non-significant Risk Medical Device Studies". PINPOINT is a 
commercially available product in the United States (US) and Canada PINPOINT has a 510(k) 
clearance from the FDA and is licensed in Canada with the following indication: 
 
“The PINPOINT system is intended to provide real-time endoscopic visible and near 
infrared fluorescence imaging. PINPOINT enables surgeons to perform routine visible 
light endoscopic procedures as well as further visually assess vessels, blood flow and 
related tissue perfusion with near infrared imaging during minimally invasive surgery”. 
 
Note: PINPOINT has not yet been classified by the FDA or Health Canada for the purposes of 
lymphatic mapping. 
 
The imaging agent, ICG, is approved for human use by the FDA and Health Canada. In this 
study, investigational ICG (IC2000) will be administered interstitially for the visualization of LN 
and LC. The safety of interstitial administration of investigational IC2000 for NIR fluorescence 
imaging to identify LN has not been studied. However, safety data from published studies 
reported above combined with the well-established safety profile for ICG after intravenous or 
intra-arterial injection support an acceptable risk/benefit ratio for interstitial administration of 
ICG. The most serious risk of ICG when administered intravenously in humans, is anaphylactic 
death, which has been reported following ICG administration during cardiac catheterization. 
 
These and other risks of the PINPOINT system in humans are described further in Section 7, 
Risks/Precautions. For additional information, please refer to the PINPOINT Operator’s 
Manual16. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 19 of 56 
Novadaq - CONFIDENTIAL 
 
 
2 STUDY OBJECTIVES 
 
2.1 Objectives 
 
2.1.1 Primary Objectives 
 
The primary objective of this study is to assess the effectiveness of intraoperative PINPOINT 
Near Infrared Fluorescence Imaging in identification of LNs in subjects with uterine and cervical 
malignancies who are undergoing LN mapping. 
 
2.1.2 Secondary Objectives 
 
 
To evaluate the effectiveness of PINPOINT and Blue dye in the identification of at least 
one LN (confirmed to be lymphoid tissue) per subject. 
 
To evaluate the effectiveness of PINPOINT and Blue dye in the identification of bilateral 
LNs (confirmed to be lymphoid tissue). 
 
To assess the safety of interstitial injection of ICG for intraoperative lymphatic mapping. 
 
To determine the proportion of LNs identified from following LCs. 
 
To find the anatomic distribution of LNs. 
 
3 INVESTIGATIONAL PLAN 
 
3.1 Study Design Overview 
 
This is a randomized prospective, open label, multicenter study to assess the safety and 
effectiveness of PINPOINT Near Infrared Fluorescence Imaging (PINPOINT) in identification of 
LN in subjects with uterine and cervical malignancies who are undergoing LN mapping. This is 
a non-inferiority within-subject comparison study to determine the effectiveness of PINPOINT in 
the identification of LNs compared to LNs identified with Blue dye. Approximately 150 subjects 
will be enrolled at up to 10 centers in North America. Prior to enrolling study subjects, 
participating surgeons at each center will be trained to perform intraoperative identification and 
mapping of LNs with ICG and Blue dye. Participating surgeons will be required to have completed 
at least 10 LN mapping procedures with a minimum of 3 LN mapping cases performed with 
PINPOINT prior to the initiation of enrollment. 
 
Screening: 
Subjects diagnosed with International Federation of Gynecology and Obstetrics (FIGO) clinical 
stage I endometrial or cervical cancer scheduled for surgery that includes clinically indicated LN 
mapping will be evaluated at baseline to determine if they meet the inclusion/exclusion criteria 
of the protocol. Subjects will be assessed to determine overall health status including 
demographics, vital signs, diagnosis and relevant medical history/underlying conditions. Eligible 
subjects who provide informed consent will be considered for inclusion into the study. 
 
 
 
 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 20 of 56 
Novadaq - CONFIDENTIAL 
 
 
FIGURE 1. Group Assignment and Randomization 
 
 
Day 0: 
On the day of surgery, subjects will be randomized (1:1) to either the BLUE-PINPOINT (B-P) 
Arm or the PINPOINT-BLUE (P-B) Arm. Subjects in each arm will be randomized according to 
an independently generated randomization scheme to undergo lymphatic mapping with Blue 
dye first followed by mapping with PINPOINT (B-P Arm) or to undergo lymphatic mapping with 
PINPOINT first followed by mapping with Blue dye (P-B Arm). 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 21 of 56 
Novadaq - CONFIDENTIAL 
 
 
Eligible subjects who have provided informed consent will be enrolled in the study upon 
randomization on the day of surgery (Day 0). Minimally invasive surgery will be performed 
according to the surgeon’s standard practice. 
The cervix will be injected four (4) times with a 1 ml solution of Blue Dye (1% Isosulfan blue; 
10 mg/ml) for a total dose of 40 mg Blue Dye) and four (4) times with 1 ml of a 1.25 mg/ml solution 
of IC2000 for a total dose of 5 mg IC2000 . The injection of Blue dye and IC2000 will occur while 
the subject is under anesthesia in the operating room. 
In order to minimize the spillage of blue dye or ICG interfering with the mapping procedure when 
LNs are excised, mapping will be performed on one side of the pelvis followed by the other side 
and mapping with both Blue dye and PINPOINT will be performed prior to the excision of any 
LNs. 
Subjects randomized into the B-P Arm will be administered Blue dye first followed by the 
administration of IC2000 and undergo LN mapping with Blue dye first followed by mapping with 
PINPOINT. LN mapping with Blue dye will be performed until the investigator identifies all blue 
nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will 
begin mapping with PINPOINT until all ‘IC2000’ nodes are identified or the investigator 
determines that ‘ICG’ nodes cannot be identified. Once mapping with both Blue dye and 
PINPOINT have been completed and documented, all LNs identified with Blue dye or PINPOINT 
will be excised. 
Subjects randomized into the P-B Arm will be administered IC2000 first followed by the 
administration of Blue dye and undergo LN mapping with PINPOINT first followed by mapping 
with Blue dye. LN mapping with PINPOINT will be performed until the investigator identifies all 
‘IC2000’ nodes or determines that ‘IC2000’ nodes cannot be identified. Once complete, the 
Investigator will begin mapping with Blue dye until all ‘blue’ nodes are identified or the 
investigator determines that ‘blue’ nodes cannot be identified. Once mapping with both 
PINPOINT and Blue dye have been completed and documented, all LNs identified with 
PINPOINT or Blue dye will be excised. 
LN mapping for Clinical Stage I endometrial cancer will be performed according to the NCCN 
Guidelines for Uterine Neoplasms, LN Algorithm for Surgical Staging of Endometrial Cancer; 
and LN mapping for Clinical Stage I cervical cancer will be performed according to the NCCN 
Guidelines for Cervical Neoplasms, Surgical/LN Mapping Algorithm for Early-Stage Cervical 
Cancer1, 2. 
The surgeon will identify LN based on direct visualization with white light for blue dye or 
PINPOINT for IC2000. 
LN Mapping with PINPOINT: 
Intraoperative identification of LNs with IC2000 will be based on the following criteria: 
 
Direct visual identification of a node by NIR fluorescence with IC2000 using PINPOINT. 
 
Visibly or palpably abnormal LNs designated as palpable masses and excised 
regardless of visible fluorescence. 
. 
 
Mapping will be considered complete when all nodes meeting any of the criteria above are 
identified and documented and the surgeon has scanned the full 360-degree area within the 
abdominal cavity. Fluorescent ducts should be followed in both directions in order to identify 
LNs to be excised. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 22 of 56 
Novadaq - CONFIDENTIAL 
 
 
LN Mapping with Blue dye: 
Intraoperative identification of LNs with Blue dye will be based on the following criteria: 
 
Direct visual identification of a node stained with Blue dye. 
 
Visibly or palpably abnormal LNs designated as palpable masses and excised regardless 
of visible blue dye. 
Mapping will be considered complete when all nodes and channels meeting any of the criteria 
above are identified and documented and the surgeon has scanned the full 360-degree area 
within the abdominal cavity. Blue ducts should be followed in both directions in order to identify 
LNs to be excised. 
Classification of LNs: 
All LNs identified will be classified as: 
1. Fluorescent only 
2. Blue only 
3. Both (Fluorescent and blue) 
4. Abnormal or palpably hard 
5. Non-stained node found at origin or termination of fluorescent duct 
6. Non-stained node found at origin or termination of blue duct 
7. Non-stained node found at origin or termination of fluorescent and blue duct 
 
Effectiveness of intraoperative Blue dye in identifying of LN will be based on the proportion of 
LNs identified by visualization of blue dye under white light and confirmed as lymphoid tissue by 
histology divided by the total number of LNs identified and excised. 
Effectiveness of intraoperative PINPOINT in identifying of LN will be based on the proportion of 
LNs identified by PINPOINT and confirmed as lymphoid tissue by histology divided by the total 
number of LNs identified and excised. 
 
 
Details of the surgery, including intraoperative findings will be documented. Surgical data will be 
collected including the ability to identify LNs, the number of LNs identified and removed, the 
ability to unilaterally and bilaterally map LNs, and the anatomical location and distribution of 
identified LNs. Failed mapping is defined as no LNs detected. 
Follow-up and Post-operative Complications: 
All Subjects will have standard of care assessments throughout the study according to the 
hospital/institution’s standard procedures as well as study specific visits to monitor occurrence 
of any adverse events/adverse device effects on the date of discharge and Day 30 (±7 days). All 
subjects will be followed to monitor occurrence of adverse events up to Day 30 (±7 days) post- 
surgery. All adverse events will be followed up to Day 30 (±7 days). Adverse events thought to 
be related to the use of PINPOINT or to the LN mapping procedure will be followed until 
resolution or deemed chronic. 
 
4 SELECTION AND WITHDRAWAL OF SUBJECTS 
 
4.1 Number of Subjects 
 
Approximately 150 subjects will be enrolled in the study (See Section 10.4). 
 
4.2 Inclusion Criteria 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 23 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
To be eligible for the study, a subject must fulfill all of the following criteria: 
 
1. Be 18 years of age or older 
2. Have either of the following diagnoses and surgical plan: 
a. FIGO Clinical stage I endometrial cancer undergoing minimally invasive 
hysterectomy with lymphatic mapping 
b. FIGO Clinical stage IA cervical cancer ≤ 2 cm undergoing minimally invasive 
hysterectomy, trachelectomy or conization with lymphatic mapping. Note: Subjects 
with clinical Stage IA1 cervical cancer without lympho vascular space involvement 
(LVSI) and negative margins on cone biopsy are not to be included. 
3. Negative nodal status (N0) 
4. Subjects with negative metastatic involvement (M0) 
5. Subjects of child-bearing potential must not be pregnant or lactating and must have a 
negative pregnancy test at Day 0 
6. Have signed an approved informed consent form for the study 
7. Be willing to comply with the protocol 
 
4.3 Exclusion Criteria 
 
A subject meeting any of the following criteria will be excluded from the study: 
 
1. Have had prior dissection and/or radiation in pelvis 
2. Advanced cervical or endometrial cancer, T3/T4 lesions 
3. Diagnosis of cervical cancer with a tumor size greater than 2 cm 
4. Locally advanced cervical or uterine cancer 
5. Metastatic cervical or uterine cancer 
6. Known allergy or history of adverse reaction to ICG, iodine or iodine dyes 
7. Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or 
triphenylmethane 
8. Hepatic dysfunction defined as MELD Score > 12 
9. Renal dysfunction defined as serum creatinine ≥ 2.0 mg/dl 
10. Subjects who have participated in another investigational study within 30 days prior to 
surgery 
11. Pregnant or lactating subjects 
12. Subjects who, in the Investigator's opinion, have any medical condition that makes the 
subject a poor candidate for the investigational procedure, or interferes with the interpretation 
of study results 
4.4 Withdrawal of Subjects 
 
Subjects can voluntarily withdraw (or be withdrawn) at any time during the study. 
Investigators may withdraw a subject from the study because: 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 24 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
A new health condition, diagnosis or finding appears that is suspected to require care or 
medication prohibited by the protocol. 
o e.g., the planned surgical procedure is modified to a procedure prohibited by the 
protocol. 
 
The subject has unacceptable adverse events. 
 
It is in the subject’s best interest according to the Investigator’s clinical judgment. 
If a subject is prematurely withdrawn from the study, the reason(s) for withdrawal must be 
recorded on the relevant page of the subject's Study Completion case report form (CRF). 
Subjects who discontinue the study prematurely will not be replaced. 
The Sponsor may stop the study at any time. 
5 RANDOMIZATION, BLINDING AND SUBJECT IDENTIFICATION PROCEDURES 
 
5.1 Randomization 
 
Subjects will be prospectively randomized into the FILM Clinical Trial. Randomization will occur 
on the day of surgery. Prior to surgery, the subject will have provided written informed consent, 
completed all baseline procedures and met the requirements of inclusion and exclusion criteria. 
Randomization should be performed as closely as possible to the mapping procedure to 
minimize the incidence of dropout. 
Subjects will be randomly assigned on a one to one (1:1) basis to either the B-P Arm (LN mapping 
with Blue dye followed by LN mapping with PINPOINT) or the P-B Arm (LN mapping with 
PINPOINT followed by LN mapping with Blue dye). Randomization will be stratified by study site. 
Permuted block randomization will be performed within strata. To minimize the opportunity for 
the sequence to be predicted, the block size will be variable and randomly chosen from small 
multiples of 2 (i.e. 2, 4 or 6). The randomization schedules will be generated in advance using a 
computerized random number generator. Investigational sites will not have access to the 
randomization schedules. 
Randomization will be accomplished using a secure web-based software (REDCap) supported 
by the Data Coordinating Center. Treatment assignment is made only after verification of proper 
informed consent execution and study eligibility. 
 
5.1.1 Randomization Procedure 
 
The study coordinator or a designee will verify that the subject is eligible and that informed 
consent has been obtained prior to initiating the randomization process. On the day of surgery 
the study coordinator will log onto the REDCap system and, after confirming the subject’s 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 25 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
eligibility, will enroll a subject and obtain the randomization assignment. The study coordinator 
will then disclose the randomization assignment to the Investigator. As this is a within-subject 
comparison study, the investigator cannot be blinded to the use of Blue dye or PINPOINT device. 
All subjects will be blinded to their randomization assignment until after the procedure. 
A subject is not randomized until randomization has been assigned by REDCap. The 
randomization procedure should not be initiated unless the study coordinator confirms that a 
subject is eligible and verifies baseline information. If any deviations occur (errors such as 
assigning incorrect randomization), the clinical site will be required to contact the Sponsor and 
await guidance on how to proceed. 
If, at any time after randomization, the subject becomes ineligible or withdraws, the subject is still 
considered randomized. If an intraoperative decision is made to perform a procedure other than 
what was intended, the subject will be categorized with respect to the definitions outlined for the 
analysis populations (see the Statistical Methods Section 10.5). 
 
5.2   Subject Identification 
 
Screening ID Number: All subjects screened for the study shall be assigned a 5-digit “screening” 
number on the Screening Log and if they are randomized, will subsequently be assigned a 
Subject Enrollment Number in the electronic data capture system. The Screening Identification 
Number shall be unique and categorize a subject in sequence of screening by an “S” followed 
by a 5-digit number. The first 2 digits identify the site and the last three digits identify the subject. 
For example, the first subject screened at site 01 is identified as screening number S- 01001. 
The screening log shall be maintained by the site to identify those subjects that have failed 
screening with the reason why they did not qualify for enrollment. The screening number will be 
assigned sequentially within each study center in order of subject presentation for screening. 
 
Enrolled Subject ID Number: Once a subject is randomized, they will be assigned a Subject 
Enrollment Number which is also a 5-digit number. The first two digits of the Subject Enrollment 
Number identify the site and the last three digits identify the subject. Each site will be given a 
Site Identification Number. For example, the first subject randomized at site 03 is identified as 
subject 03-001, the next subject as 03-002, etc. 
 
Subjects who sign an informed consent form but are not randomized are considered screen 
failures. These subjects must be entered on the Screening Log but do not receive a subject 
number. The reason for non-enrollment must be documented on the log. 
 
6 STUDY TREATMENTS 
 
6.1 Device Description 
 
PINPOINT is an endoscopic fluorescence imaging system for high definition (HD) visible (VIS) 
light and near-infrared (NIR) fluorescence imaging. PINPOINT includes the following 
components: 
 
A surgical endoscope optimized for VIS/NIR illumination and imaging, which is available in 
different diameters, lengths and directions of view (Model: SC9104, SC9134). 
 
A camera head that is also optimized for VIS/NIR imaging and mounts to the endoscope 
eyepiece (Model: PC9002). 
 
A flexible light guide cable (Model: PC9004). 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 26 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
An endoscopic Video Processor / Illuminator (VPI) capable of providing VIS/NIR illumination 
to the surgical endoscope via a flexible light guide cable, and the image processing required 
to generate simultaneous, real-time HD video color and NIR fluorescence images (Model: 
PC9001). 
PINPOINT is designed to be connected to a medical-grade HD color monitor, such as those 
normally used in surgical endoscopy. 
PINPOINT is connected to a high-definition medical video recorder (Sony HVO-1000) that allows 
the capture of still images and video during operation. 
PINPOINT acquires NIR fluorescence images of an imaging agent (IC2000) to allow for visual 
assessment of vessels, blood flow and related tissue perfusion during minimally invasive surgery. 
For the purpose of this study, PINPOINT will be used for visual identification of LNs during LN 
mapping procedures. 
 
The PINPOINT Operator’s Manual16 describes the contents, use and storage of the PINPOINT 
PAQ’s. Instructions for preparation, handling and administration of Investigational ICG (IC 2000) 
are provided in Section 8.3.1.2. 
 
PINPOINT allows simultaneous display of multiple images. Real time NIR fluorescence video 
images are acquired by using the imaging agent and may be viewed in two ways: 
 
PINPOINT image: 
NIR fluorescence is superimposed in pseudo-color (green) on a white light 
image 
SPY image: 
A black and white NIR fluorescence image is displayed 
CSF: 
A high-definition, white light image is displayed in 
grayscale with NIR fluorescence overlaid on a color scale. Increasing 
fluorescence levels transition from blue through yellow to red. 
 
PINPOINT also operates as a conventional endoscopic imaging system and provides 
illumination for real-time color (white light) HD video imaging in the area of interest. 
 
PINPOINT is a commercially available product in the United States (US) and Canada. 
PINPOINT has a 510(k) clearance from the FDA and a Health Canada license with the 
following indication: 
“The PINPOINT system is intended to provide real-time endoscopic visible and near 
infrared fluorescence imaging. PINPOINT enables surgeons to perform routine visible 
light endoscopic procedures as well as further visually assess vessels, blood flow and 
related tissue perfusion with near infrared imaging during minimally invasive surgery”. 
 
PINPOINT is manufactured by Novadaq Technologies Inc. (Novadaq). Please refer to the current 
version of the PINPOINT Operator’s Manual16 for a full description and specifications of the 
system. 
 
In this study, the use of PINPOINT for visual identification of lymph nodes via interstitial injection 
of ICG is investigational. 
 
6.2 Imaging Agent Description 
 
6.2.1 Indocyanine Green IC2000 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 27 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
6.2.1.1 Overview and Pharmacokinetics of Investigational Product 
 
ICG was originally approved by the FDA for human medical use in 1959 for use in determining 
cardiac output, hepatic function and liver blood flow. In 1975, a NDA Supplement was approved 
for ICG for use in ophthalmic angiography. In 2005, ICG was approved under a 510K for 
assessing blood flow and tissue perfusion in a variety of surgical and non-surgical procedures. 
Over the past 50 years ICG has been marketed in the United States and has demonstrated an 
excellent safety profile. ICG has received approval from Health Canada (DIN 02014793) in 1994 
for human medical use as a diagnostic agent, and is classified as an “Ethical” drug. 
ICG absorbs light in the near-infrared (NIR) region at 806 nm and emits fluorescence (light) at a 
slightly longer wavelength, 830 nm. After injection, ICG rapidly binds to blood proteins primarily 
lipoproteins and to a lesser extent globulins and albumin and drains into the lymphatic system 
without extravasation enabling sensitive non-invasive visualization of LN and lymphatic 
architecture. Within minutes after intravenous injection, ICG is cleared by the liver and excreted 
into the bile24. Since lymph fluid flows into the venous blood stream through the subclavien veins9, 
it is assumed that, after interstitial injection, ICG drains with lymph fluid into the circulatory system 
where it is then cleared by the liver and excreted in the bile. Although formal pharmacokinetic 
studies have not been performed with non-intravenous routes of administration, after intradermal 
injection in mice, ICG was shown to be taken up by lymphatic vessels and cleared within 48 
hours29,30. Another study using ICG conjugated to human serum albumin (HSA) in rabbits found 
ICG is efficiently taken up by the lymphatic vessels and cleared within 24 hours after peritumoral 
injection31. Chi et al. investigated the use of ICG for LN mapping in 5 mice, 10 rabbits and 22 
breast cancer subjects and found LNs are identifiable 3-5 minutes after injection with the 
occurrence of peak fluorescence intensities varying with the dose of ICG and occurs between 10 
and 90 minutes32. 
6.2.1.2 Description of Investigational Product (IC2000) 
 
The chemical name of the investigational drug, indocyanine green is 1 H-Benz[e]indolium, 2-[7- 
[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1- 
dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. ICG has a molecular weight of 
774.96 daltons and will be administered with an interstitial injection into the cervix. 
 
The imaging agent , IC2000 (indocyanine green, USP) is provided in the form of a sterile lyophilized 
powder containing 25 mg ICG with no more than 5% sodium iodide. IC2000 is packaged with 
aqueous solvent consisting of sterile Water for Injection, which is used to reconstitute the ICG. 
When injected, ICG rapidly and extensively binds to plasma proteins (primarily lipoproteins and 
globulins) with minimal leakage through vessel walls. This property makes ICG an ideal agent for 
the acquisition of high quality images of LNs and s (i.e., for NIR fluorescence lymphography). Note: 
The use of IC2000 in this study is investigational. 
 
6.2.1.3 Chemistry and Manufacturing 
 
Investigational IC2000 is supplied as a 25 mg sterile lyophilized green powder in a glass vial with 
a grey stopper and grey over seal. The product is stored at 20°C to 25°C (68° to 77° F).  IC2000 
is manufactured by Patheon (Patheon Italia S.p.A., 2° Trav. SX Via Morolense, 503013 
Ferentino- Italy) and, like commercially available ICG, IC2000 is tested according to the USP 
monograph for Indocyanine green for Injection. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 28 of 56 
Novadaq - CONFIDENTIAL 
 
 
IC2000 was manufactured in full compliance with the FDA’s current Good Manufacturing Practice 
(cGMP) for Finished Pharmaceuticals-standards at 21 CFR Part 211 and meets all GMP 
requirements for Health Canada. 
 
6.2.1.4 Labelling of IC2000 for Injection 
 
IC2000 is labeled according to US and Canadian regulatory requirements with the following 
information: 
 
 
IC2000 (indocyanine green for injection, USP), 25 mg lyophilized ICG 
 
Sterile 
 
Protocol No.: PP LMN 01 
 
Directions for use: Refer to Clinical Protocol 
 
Store at: 20–25°C (68-77°F) 
 
Lot: 14GRF03 
 
EXP.: May 2016 
 
CAUTION—New drug - Limited by Federal (or United States) law to investigational use. 
 
Investigational drug to be used only by a qualified investigator. 
 
Sponsor: Novadaq Technologies Inc. 13155 Delf Place, Unit 250, Richmond, BC, 
Canada, V6V 2A2  1.844 6682327 
 
 
6.2.1.5 
Packaging and Distribution of IC2000 
 
IC2000 will be packaged into investigational PINPOINT LN Mapping Kits as described below and 
distributed by the study Sponsor (Novadaq). Each LN-mapping procedure kit is indicated for use 
exclusively with PINPOINT and should only be used for the purposes of this study. 
Each PINPOINT LN Mapping kit contains: 
 
 
One single use 25 mg vial of sterile IC2000, USP 
 
Two single use 10 ml ampules of sterile Aqueous solvent 
 
Four 3 ml syringes, sterile 
 
Two 10 ml syringes, sterile 
 
Two Lure-lock 10 ml syringes with controlled handle 
 
Four Spinal needles, 22G, 3.5 inch, sterile 
 
Labels for syringes 
All information included on the investigational IC2000 for Injection vial labels will appear on the 
kit labels along with a description of the contents of the kit. Each kit will bear a unique serial 
number and will meet regulatory requirements necessary for each participating country. 
 
6.2.1.6 Storage and administration of IC2000 for Injection 
 
IC2000 will be stored at 20°C to 25°C (68° to 77° F) in a secure locked area, accessible to 
authorized personnel only. IC2000 will be stored, handled, prepared and administered by 
qualified, trained personnel only as described in Section 8.3.1.2. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 29 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
6.2.2 Blue Dye (Isosulfan Blue) 
 
The Blue dye (Isosulfan Blue Injection, 1% aqueous solution) a sterile and pyrogen-free 5 ml 
single-use vial33. Isosulfan blue is supplied as a 1% aqueous solution in a phosphate buffer and 
is approved under an ANDA by the US FDA for the identification of lymphatic vessels draining 
the region of injection, lymphography, and identification of lymph node involvement by primary 
and secondary neoplasms. Isosulfan blue will be obtained from commercially available sources 
and is approved for subcutaneous injection. 
 
6.2.2.1   Storage and administration 
 
Blue dye will be stored at 20°C to 25°C (68° to 77° F) in a secure locked area, accessible to 
authorized personnel only. Blue dye will be stored, handled, prepared and administered by 
qualified, trained personnel only as described in Section 8.3.1.1. 
 
 
Installation, Training and Storage 
PINPOINT will be installed by Novadaq representatives. The Investigator(s) and study staff shall 
be required to participate in training on the operational and procedural use of PINPOINT as it 
relates to the conduct of this study. Training will be provided by Novadaq. 
 
Prior to enrollment, participating Investigator surgeons must be experienced with LN mapping 
procedures (i.e. performed a minimum of 10 LN mapping procedures) with a minimum of 3 LN 
mapping cases performed with PINPOINT prior to initiation of enrollment. 
 
Investigator surgeons new to this technique will receive training consisting of the following: 
 
 
Didactic training on product and procedure. 
 
Hands on training session with clinical specialists on site. 
 
Guidance on use of the system and interpretation of the images with a clinical educator 
during a minimum of 10 cases prior to study enrollment. 
Supporting personnel operating and cleaning PINPOINT will also receive training and be familiar 
with all applicable aspects of the operation and cleaning of the system. 
 
PINPOINT shall be stored at room temperature in a secure and limited access area available to 
study staff. 
 
6.3   Concomitant Treatment 
 
Any concomitant medications the subject is receiving at the start of the study (Day 0) or given 
for any reason during the study must be recorded in the CRF and source documents with the 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 30 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
exception of routine medications given for preparation of surgery, during surgery and post- 
operative care. These include but are not limited to the following: 
 
 
Sedatives and anesthetics 
 
Anticoagulants 
 
Prophylactic antibiotics 
 
Anti-emetics 
 
Routine post-operative pain medications 
 
The drug name, start and stop dates, indication, dose, frequency and route information will be 
recorded for concomitant medications. 
 
Other surgical and diagnostic procedures concomitant to the laparoscopic hysterectomy, 
trachelectomy, conization and lymphatic mapping procedure that take place during the study 
must be recorded in the CRF and in the source document, including start and stop dates. 
 
7 RISKS/PRECAUTIONS 
 
Refer to the PINPOINT Operator’s Manual for a full description of the risks and precautions 
associated with all components of PINPOINT. The entire PINPOINT Operator’s Manual should 
be read before using PINPOINT16. Failure to follow the instructions and warnings in the manual 
may result in unsafe operation of the system and/or injury to the subject or operator. 
 
Refer to the Isosulfan Blue prescribing information for a full description of risks and precautions 
associated with the use of Isosulfan Blue33. The entire package insert should be read before 
using Isosulfan blue. Failure to follow instructions and warnings may result in injury to the subject. 
 
7.1 PINPOINT System – Endoscopes, Camera and Video Processor Illuminator Unit 
 
Currently, PINPOINT is classified by the FDA as a Class II medical device with a Product Code 
of GCJ. PINPOINT for the purposes of fluorescence angiography is not identified as a significant 
risk device on the FDA Information Sheet titled "Significant Risk and Non-significant Risk Medical 
Device Studies". 
 
The use of PINPOINT for LN mapping is investigational. PINPOINT should only be used in 
accordance to its approved Indication for Use or in accordance to the study procedures described 
in this protocol. 
 
7.2 Indocyanine Green (IC2000) 
 
IC2000 will be injected directly into the cervical submucosa and stroma; and will not be 
administered intravenously. Additionally, the subject is anesthetized and the cervix and uterus 
are removed as part of the surgical procedure. Therefore the risks associated with injection into 
the cervix are expected to be lower than those associated with intravenous administration. Based 
on the clinical information for systemic ICG administration, the risks and precautions are 
discussed below. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 31 of 56 
Novadaq - CONFIDENTIAL 
 
 
Severe allergic reaction (affects fewer than one in every 10,000 subjects) with symptoms that 
could include the following: tightness in the throat, itchy skin, blotchy skin, rash, coronary artery 
spasm, facial edema, breathing difficulties, tightness and/or pain in the chest, faster heartbeat, a 
fall in blood pressure and shortness of breath, cardiac arrest, restlessness, nausea, feeling of 
warmth, flushes, hypereosinophilia15. 
The possibility of an allergic reaction is greater in subjects with extremely serious kidney failure. 
To minimize the risk of an allergic reaction, all subjects with renal dysfunction are excluded as 
well as subjects with a known allergy to iodine, ICG or iodine dyes15. 
 
IC2000 contains sodium iodide and should be used with caution in subjects who have a history 
of allergy to iodides or iodinated imaging agents. Anaphylactic or urticarial reactions have been 
reported in subjects with and without history of allergy to iodides. Anaphylactic deaths have been 
reported following ICG administration during cardiac catheterization14. 
 
Radioactive iodine uptake studies should not be performed for at least 1 week following IC2000 
administration14,15. 
 
Animal reproduction studies have not been conducted with ICG or IC2000. It is not known 
whether ICG or IC2000 can cause fetal harm when administered to a pregnant woman or can 
affect reproduction capacity. It is not known whether ICG or IC 2000 is secreted in human milk. 
Women who are pregnant or lactating are excluded from this study. 
 
7.3 Isosulfan Blue (Blue Dye) 
 
Similar to the administration of IC2000 in this study, Isosulfan blue will be directly injected into 
the cervical submucosa and stroma. The subject will be anaesthetized and the cervix and uterus 
are removed as part of the surgical procedure. 
 
Severe anaphylactic reactions have occurred after injection of Isosulfan blue (approximately 2% 
of subjects). Manifestations include respiratory distress, shock, angioedema, urticarial and 
pruritus. Reactions are more likely to occur in subjects with a history of bronchial asthma, or 
subjects with allergies or drug reactions to triphenylmethane dyes. 
 
Isosulfan blue interferes with measurements of oxygen saturation by pulse oximetry and 
methemoglobin by gas analyzer. 
 
The use of Isosulfan blue may result in transient of long-term (tattooing) blue coloration. 
 
It is not known whether Isosulfan blue can cause fetal harm when administered to a pregnant 
woman or can affect reproduction capacity. It is not known whether Isosulfan blue is secreted in 
human milk. Women who are pregnant or lactating are excluded from this study. 

 
PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
 
8 STUDY PROCEDURES 
 
8.1 Schedule of Events 
 
Table 3 Schedule of Events 
 
Procedure 
Baseline 
(Day -30 to Day 
0) 
Day 0  (Operative Phase) 
Pre-OP 
Intra-Op 
Post-Op 
Date of Discharge 
Day 30 Phone call 
(+ 7 days) a 
Informed consent 
X 
 
Demography, Surgical risk factors 
X 
 
Vital signs, blood pressure, heart rate, 
height, weight 
X 
 
Pre-operative diagnosis 
X 
 
Pregnancy test 
X 
 
Inclusion/exclusion criteria 
X 
 
Serum sodium, bilirubin, creatinine and INR 
for MELD Score 
X 
 
Hemoglobin 
Xd 
Xb 
 
Randomization 
X 
 
LN mapping with Blue dye 
X 
 
LN mapping with PINPOINT 
X 
 
Surgical Procedure 
X 
 
Documentation of LN mapping and surgical 
procedure 
X 
X 
 
Concomitant medications and procedures 
X 
X 
X 
X 
X 
X 
Adverse events/adverse device effects 
X 
X 
X 
X 
Xc 
Histopathological evaluation of Lymph 
Nodes 
X 
X 
 
a 
Subjects with a discharge date later than Day 30, will have the last study visit on Day 30. 
b 
Hemoglobin measurement at the time of mapping if the subject had any hypotensive events or blood loss over 500 ml at the time of mapping. 
c 
All subjects with adverse events thought to be related to the LN mapping procedure or the PINPOINT system will be followed until resolution or deemed chronic. 
d    Hemoglobin measurement must occur within 14 days prior to the day of surgery (Day -14 to day 0) 
 
Page 32 of 56 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 33 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
 
8.2 Baseline/Screening Procedures (Day -30 to Day 0) 
 
After signing the informed consent form, subjects will be assigned a screening number (see 
Section 5.2) and be evaluated for eligibility into the study. 
 
The following procedures will be conducted during the baseline assessment: 
 
 
Collection of demographics, surgical risk factors, pre-operative diagnosis 
 
Vital signs (heart rate and blood pressure), height and weight 
 
Serum tests (sodium, bilirubin, creatinine and INR) for MELD Score 
o The following calculator from the OPTN website should be used to calculate the 
MELD Score: 
 
 
https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/ 
 
 
 
Pregnancy test (urine test or institution standard of care) for subjects of childbearing 
potential on Day 0 
 
Hemoglobin measurement within 14 days prior to the date of surgery. 
 
8.3 Day 0 Procedures 
 
On the day of surgery, subjects will be randomized as described in Section 5.1. Subjects are 
considered enrolled upon randomization. 
 
According to the randomization assignment, subjects randomized into the B-P Arm will be 
administered Blue dye first followed by the administration of IC2000. Subjects in the B-P arm 
will undergo LN mapping with Blue dye first followed by mapping with PINPOINT. 
 
Subjects randomized into the P-B Arm will be administered IC2000 first followed by the 
administration of Blue dye and undergo LN mapping with PINPOINT first followed by mapping 
with Blue dye. 
 
All subjects will undergo the appropriate surgical procedure (minimally invasive hysterectomy, 
trachelectomy or conization) according to the surgeon’s standard practice. The surgical 
procedures include the following: 
 
 
Hysterectomy, Radical Hysterectomy 
 
 
Radical Trachelectomy 
 
 
Bilateral Salpingo-ophorectomy, Unilateral Salpingo-ophorectomy 
 
 
Ovarian Transposition 
 
 
Sentinel Lymph Node Mapping 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 34 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
 
Pelvic Lymph Node Sampling 
 
 
Pelvic Lymph Node Dissection 
 
 
Para-aortic Lymph Node Sampling 
 
 
Para-aortic Lymph Node Dissection 
 
All subjects will receive the hospital/institution and surgeon’s standard pre-operative 
and post- operative care with the addition of any study specific requirements. 
An intra-operative measurement of hemoglobin should be performed at the time of 
mapping if the subject experiences a hypotensive event requiring intraoperative 
management (e.g. use of vasopressors) or blood loss greater than 500 ml at the time of 
mapping. 
 
Either during or immediately post-operatively, the details of the LN mapping procedure 
and surgical procedure will be documented. LN mapping data will be collected including 
the ability to identify LN, the ability to unilaterally and bilaterally map LN, and anatomical 
location and distribution of identified LN. Failed mapping is defined as no LN detected. 
 
The following elements must be included and recorded in the case report form (CRF): 
 
Surgical time and estimated blood loss 
 
Dose of Blue dye administered 
 
Dose of IC2000 administered 
 
Details on injection technique 
 
Total number of LNs identified with PINPOINT 
 
Total number of LNs identified with Blue dye 
 
Total number of abnormal LNs identified (suspicious nodes) 
 
Total number of LNs excised 
 
Classification of LNs identified 
 
LNs anatomical location and distribution 
 
Pathological status of LNs excised 
 
Concomitant medications and procedures as described in Section 6.3 
 
Adverse events according to Section 9 
 
8.3.1 Lymph Node Mapping Procedure 
 
LN mapping for FIGO Clinical Stage I endometrial cancer will be performed according 
to the NCCN Guidelines for Uterine Neoplasms, SLN Algorithm for Surgical Staging 
of Endometrial Cancer1. 
 
LN mapping for FIGO Clinical Stage I cervical cancer will be performed according to the 
NCCN Guidelines for Cervical Neoplasms, Surgical/SLN Mapping Algorithm for Early-
Stage Cervical Cancer, 2. 
 
In order to minimize the spillage of blue dye or IC2000 interfering with the mapping 
procedure when LNs are excised, mapping will be performed on one side of the pelvis 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 35 of 56 
Novadaq - CONFIDENTIAL 
 
 
followed by the other side of the pelvis, and LN mapping with both Blue dye and 
PINPOINT will be completed prior to the excision of any LNs. 
 
According to the randomization assignment, subjects randomized into the B-P Arm will be 
administered Blue dye first followed by the administration of IC2000. Blue dye and IC2000 will 
be prepared in separate syringes and administered into the cervix at the three and nine o’clock 
position with a superficial and deep injection. Subjects in the B-P Arm, will undergo LN mapping 
with Blue dye first followed by mapping with PINPOINT. LN mapping with Blue dye will be 
performed until the investigator identifies all blue nodes or determines that blue nodes cannot 
be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 
‘IC2000’ nodes are identified or the investigator determines that ‘IC2000’ nodes cannot be 
identified. Once mapping with both Blue dye and PINPOINT have been completed and 
documented, all LNs identified with Blue dye or PINPOINT will be excised. 
 
 
Subjects randomized into the P-B Arm will be administered IC2000 first followed by the 
administration of Blue dye. Similar to the B-P Arm, IC2000 and Blue dye will be prepared in 
separate syringes and administered into the cervix at the three and nine o’clock position with 
a superficial and deep injection. Subjects in the P-B Arm, will undergo LN mapping with 
PINPOINT first followed by mapping with Blue dye. LN mapping will be performed until the 
investigator identifies all ‘IC2000’ nodes or determines that ‘IC2000’ nodes cannot be identified. 
Once complete, the Investigator will begin mapping with Blue dye until all ‘blue’ nodes are 
identified or the investigator determines that ‘blue’ nodes cannot be identified. Once mapping 
with both Blue dye and PINPOINT have been completed and documented, all LNs identified 
with Blue dye or PINPOINT will be excised. 
. 
 
The Investigator will identify ‘Blue’ nodes and ‘IC2000’ nodes based on direct visualization with 
white light for Blue dye and PINPOINT for IC2000 according to Section 8.3.1.3 and 8.3.1.4 
respectively. All nodes identified during the mapping procedure will be classified according to 
Section 8.3.1.5 and recorded in the operative CRFs. 
 
8.3.1.1 Imaging Agent Dosing and Administration of Blue dye 
The Blue dye solution will be prepared and administered by the appropriate qualified study 
and/or operating room personnel according to the method of Abu Rustum4. The cervix will be 
injected with Blue dye while the subject is under anesthesia in the operating room, 
approximately 15 minutes prior to planned mapping. 
 
 
One vial of Isosulfan Blue (1% solution) will be utilized A 22G spinal needle will be used 
to inject Blue dye at the 3 and 9 o’clock positions. 
 
At each position, a superficial (1-3 mm) and a deep (1-3 cm) injection of 1 mL of Blue 
dye will be made into the cervical submucosa and stroma. Blue dye should be injected 
at a rate of 5 to 10 seconds per injection. 
 
Total dose of Isosulfan blue administered will be 40 mg (10 mg/ml Isosulfan Blue, 4 x 1 
ml injections/subject) 
 
8.3.1.2 Imaging Agent Dosing and Administration of IC2000 
Similar to administration of Blue dye solution, the IC2000 solution will be prepared and 
administered by the appropriate qualified study and/or operating room personnel according to 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 36 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
the method of Abu Rustum4. The cervix will be injected with IC2000 while the subject is under 
anesthesia in the operating room, approximately15 minutes prior to the planned time of 
imaging. 
 
One 25 mg vial of IC2000 will be reconstituted with 20 ml sterile water for injection to 
yield a 1.25 mg/ml solution immediately prior to IC2000 administration. 
 
A 22G spinal needle will be used to inject IC2000 at the 3 and 9 o’clock positions. 
 
At each position, a superficial (1-3 mm) and a deep (1-3 cm) injection of 1 mL of IC2000 
will be made into the cervical submucosa and stroma. 
 
IC2000 should be injected at a rate of 5 to 10 seconds per injection. 
The total dose of IC2000 administered will be 5 mg (4 x 1 ml injections/subject). 
8.3.1.3 Identification of Lymph Nodes with Blue Dye 
Intraoperative identification of LNs with Blue dye will be based on the following criteria: 
 
Direct visual identification of a node stained with Blue dye. 
 
Visible or palpably abnormal LNs designated as palpable masses and excised 
regardless of visible blue dye. 
Mapping will be considered complete when all nodes meeting any of the criteria above are 
identified, classified and documented and the surgeon has scanned the full 360-degree area 
within the abdominal cavity. Blue ducts should be followed in both directions in order to identify 
LNs to be excised. 
 
8.3.1.4 Identification of Lymph Nodes with PINPOINT 
Intraoperative identification of LNs with PINPOINT will be based on the following criteria: 
 
Direct visual identification of a node by NIR fluorescence with IC2000 using PINPOINT. 
 
Visibly or palpably abnormal LNs designated as palpable masses and excised 
regardless of visible fluorescence. 
Mapping will be considered complete when all nodes meeting any of the criteria above are 
identified, classified and documented and the surgeon has scanned the full 360-degree area 
around the injection site. Fluorescent ducts should be followed in both directions in order to 
identify LNs to be excised. Once all ‘IC2000’ nodes have been identified 
8.3.1.5 Classification of Lymph Nodes 
All LNs identified will be classified as: 
1. Fluorescent only 
2. Blue only 
3. Both (Fluorescent and blue) 
4. Abnormal or palpably hard 
5. Non-stained node found at termination of fluorescent duct 
6. Non-stained node found at termination of blue duct 
7. Non-stained node found at termination of fluorescent and blue duct 
 
All LN identified and subsequently removed will be histologically examined to confirm the 
presence of lymphoid tissue according to section 8.5. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 37 of 56 
Novadaq - CONFIDENTIAL 
 
 
8.3.1.4.1   National Comprehensive Cancer Network Guidelines 
The LN mapping procedure for subjects with uterine neoplasms will be performed according to 
the guidelines from the NCCN for Uterine Neoplasms, SLN Algorithm for Surgical staging of 
Endometrial Cancer1 (Figure 2) in addition to the removal of other LNs according to standard 
of care. 
 
 
 
 
 
 
FIGURE 2. SLN Algorithm for Surgical Staging of Endometrial Cancer 
 
 
 
 
 
The LN mapping procedure for subjects with cervical neoplasms will be performed according 
to the guidelines from the NCCN for Cervical Neoplasms, Surgical/SLN Mapping Algorithm for 
Early-stage Cervical Cancer2 (Figure 3) in addition to the removal of other LNs according to 
standard of care. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 38 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
FIGURE 3. SLN Algorithm for Surgical Staging of Cervical Cancer 
 
 
 
8.4 Post-operative Follow-up Visits (Day of discharge to Day 30) 
 
Subjects will have standard of care assessments throughout the study according to the 
hospital/institution’s standard procedures as well as study specific visits on the date of discharge 
and Day 30 (±7 days). Day 30 visit will be a telephone call and subjects will be assessed for the 
following throughout the study: 
 
 
Concomitant medications and procedures as described in section 6.3 
 
Adverse events and adverse device effects according to section 9 
 
Although the subject may be seen by various individuals post-surgery, the study-specific visits 
must be conducted by a surgeon who is part of the study and has signed the Signature and 
Delegation Log. Any adverse events/adverse device effects, complications and outcomes of the 
study that occur between visits will be documented at the next study required visit. 
 
8.5 Histopathology of Excised LN 
 
The presence of lymphoid tissue for each excised LN will be confirmed by tissue analysis. All 
LNs will be routinely sectioned and stained with hematoxylin and eosin (H&E). LN ultra-staging 
will be performed according to the method of Kim et al.34. Briefly, two adjacent 5-µm sections 
will be cut and sectioned at each of the two levels, 50-µm apart from each paraffin block. 
Sections at each level will be stained with H&E and with immunohistochemistry using anti- 
cytokeratin AE1:AE3. Image Acquisition and Transmission 
 
Videos of the image sequences acquired using PINPOINT will be recorded to a medical grade 
video recorder. All required images will be provided to the Sponsor by the Investigative Center. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 39 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
Image files will be identified using the subject number and initials only (no information identifying 
the subject shall be included in the files). 
 
9 EVALUATION, RECORDING, AND REPORTING OF ADVERSE EVENTS 
 
All untoward medical occurrences either observed by the Investigator or one of his/her medical 
collaborators, or reported by the subject spontaneously, or in response to the direct question 
below, will be reported as follows: 
 
 
All events occurring before randomization should be recorded in the source documents and 
will be considered part of the subject’s case history. 
 
 
All adverse events occurring during the study will be recorded as adverse events on the 
adverse event CRF. 
 
 
Events occurring as a result of the surgery will be reported as adverse events related to the 
surgical procedure in the adverse event CRF. 
 
 
Events related to PINPOINT will be recorded as adverse device effects in the CRF. 
o Events that are not related to PINPOINT shall be recorded as adverse events. 
 
Events related to PINPOINT that affect a user of the device (non-subject) are recorded as 
technical complaints. 
 
Events related to IC2000 and/or Blue dye will be recorded as adverse events related to 
IC2000 and/or blue dye in the adverse event CRF. 
In an attempt to optimize consistency of AE reporting across centers, the subjects must be 
asked a standard question to elicit events. At each clinic or telephone evaluation of the subject, 
study personnel will ask the following questions: “Have you had any problems since your last 
visit?” 
AEs reported on the CRF will include the date of onset, severity, relationship to PINPOINT, 
IC2000 and/or Blue dye, relationship to surgical procedure, date of resolution (or the fact that  it 
is ongoing or has become chronic), action taken, and whether the AE is serious or not. 
 
9.1   Definitions 
 
9.1.1 Adverse Event (AE) 
 
Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs 
(including an abnormal laboratory findings) in subjects whether or not related to the 
investigational medical device. 
 
Includes events related to the IC2000 or Blue dye. 
 
 
Includes events related to procedures involved (any procedure in the clinical investigation 
plan). 
 
 
Postoperative nausea or vomiting occurring during the first 24 to 48 hours, and post- 
operative pain related to surgical procedure is not considered an adverse event. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 40 of 56 
Novadaq - CONFIDENTIAL 
 
 
9.1.2 Adverse Device Effect (ADE) 
 
Any adverse event related to the use of PINPOINT (includes all hardware components). 
 
 
Includes any event that is a result of a use error or intentional misuse. 
ADEs that affect subjects will be recorded as ADEs in the AE CRF. ADEs that only affect 
a user (non-subject) are recorded in the technical complaint form only. 
 
9.1.3 Serious Adverse Event 
(SAE) Any adverse event that: 
a. Led to a death. 
 
b. Led to a serious deterioration in health that either: 
 
i. 
Resulted in a life-threatening illness or injury, 
 
ii. 
Resulted in a permanent impairment of a body structure or a body function, 
 
iii. 
Required in-patient hospitalization or prolongation of existing hospitalization, 
 
iv. 
Resulted in medical or surgical intervention to prevent life threatening illness 
or injury or permanent impairment to a body structure or a body function. 
 
c. Led to fetal distress, fetal death or a congenital abnormality or birth defect. 
 
This includes device deficiencies that might have led to a serious adverse event if suitable action 
had not been taken; intervention had not been made, or if circumstances had been less 
fortunate. These are handled as SAEs. A planned hospitalization for pre-existing condition, or 
a procedure required by the protocol, without a serious deterioration in heath, is not considered 
to be a serious adverse event. 
 
9.1.4 Unanticipated Adverse Device Effect 
(UADE) Any ADE that meets the following: 
 
By its nature, incidence, severity or outcome has not been identified in the current version 
of the PINPOINT risk analysis report. 
 
On health or safety, any life-threatening problem or death caused by, or associated with a 
device, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the application; or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects. 
 
9.2   Adverse Event Descriptions 
 
9.2.1 Intensity 
 
The intensity of AEs, including ADEs will be characterized as mild, moderate, or severe, as 
follows: 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 41 of 56 
Novadaq - CONFIDENTIAL 
 
 
Mild 
Usually transient, requiring no special treatment, and does   not interfere 
with the subject’s daily activities. 
 
Moderate 
Introduces a low level of inconvenience or concern to the subject and may 
interfere with daily activities, but is usually ameliorated by simple 
therapeutic measures. 
 
Severe 
Significantly interferes with a subject’s usual daily activities and requires 
systemic drug therapy or other treatment, if available. 
 
9.2.2 Relationship 
 
Suspected 
There is a reasonable possibility that the AE is associated with use of the 
study device or treatment (IC2000 or Blue dye), such as temporal 
relationship of the event to use. 
 
Not suspected 
A relationship between the AE and the study device or treatment (IC2000 
or Blue dye) can reasonably be ruled out based on lack of any temporal 
relationship of the event to use, or when the subject’s underlying 
condition, medical history, or other therapy provide sufficient explanation 
for the observed event. 
 
9.3 Reporting and Evaluation of Serious Adverse Events and Unanticipated Adverse 
Device Effects 
 
Any SAE or UADE occurring in this study must be reported immediately (within 24 hours of 
discovery) by email to the Novadaq contact listed below: 
 
Attention: Alicia Wilton 
 
Mobile: 
905-629-3822 x209 
 
Email: Film@novadaq.com 
 
SAEs and UADEs will be reported to the Institutional Review Board (IRB)/Ethics Committee 
(EC) according to the institution’s policies, but within 10 days of occurrence. 
 
The Sponsor will be responsible for reporting SAEs/UADEs to the FDA or Health Canada in 
accordance with federal regulatory requirements. 
 
The Sponsor will provide documentation of reportable events to the Investigator, as specified in 
Section 13.1.4. 
 
The Investigator will ensure that the subject receives appropriate medical treatment and that 
the subject is followed up until the SAE or UADE resolves or becomes chronic, as defined in 
Section 9.4. 
 
9.4 Follow-up for Adverse Device Effects and Adverse Events 
 
Throughout the study to the final study visit contact, ADEs will be followed until they resolve or 
become chronic. All AEs will be followed throughout the study until the Day 30 visit. All AEs 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 42 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
related to the PINPOINT, IC2000, Blue dye or the mapping procedures, as determined by the 
Investigator, will be followed until resolution or deemed chronic 
 
At the final study visit, new AEs, as well as follow-up information for continuing AEs, will be 
recorded in the CRF and source document. If an SAE or UADE is unresolved at the final study 
visit, it will be followed by the Investigator until it resolves or becomes chronic (as judged by the 
Investigator). Follow-up data for such SAEs will be recorded in the source document and 
reported to the safety contacts. Non-serious ongoing AEs will be followed beyond the final study 
visit if they are related to the study procedures at the discretion of the Investigator. 
 
9.5 Reporting of Technical Complaints/Device Deficiencies 
 
9.5.1 Definitions 
 
Device Complaint: A quality complaint received in writing, electronically, or orally that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a device product. (In this definition, "effectiveness" refers to the actual function 
of the device, not to how the subject responds to the action of the device. Also in this definition, 
"device product" refers only to devices provided by the Sponsor for clinical studies and to 
investigational devices.) 
 
In this definition, safety includes the safety of a subject, user, or other person associated with 
the use of a medical device. 
 
Device Deficiency: Inadequacy of a medical device with respect to its identity, quality, durability, 
reliability, safety or performance. Device deficiencies include malfunctions, use errors and 
inadequate labelling. 
 
9.5.2 Reporting Procedures 
 
Any technical complaint/device deficiency should be reported to the Sponsor. Technical 
Complaints occurring in this study must be reported immediately (within 24 hours) by fax or email 
to the appropriate Novadaq representative or to Novadaq Quality (quality@novadaq.com) 
 
Any complaint about a device must be reported regardless of whether the defect or deficiency 
had any effect on a subject or on study personnel. 
 
9.6   ADEs Technical Complaints/Device Deficiencies that are UADEs 
 
Novadaq will evaluate all ADE reports and technical complaints/device deficiencies to determine if 
the report meets the definition of an unanticipated adverse device effect. If Novadaq determines 
that it does meet the definition, an investigation will be begun immediately. Novadaq will inform 
the Investigator of any additional reporting requirements beyond those stated in Sections 9.4 
and 9.5 as applicable. 
 
Novadaq will report the UADE and the results of any investigations to the FDA and Health 
Canada according to the applicable regulatory guidelines. Novadaq will also report to the 
Investigator(s), who will submit the required reports to their IRB/ECs within 10 working days after 
Novadaq first received notice of the effect. 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 43 of 56 
Novadaq - CONFIDENTIAL 
 
 
10 STATISTICAL CONSIDERATIONS 
 
10.1 Primary Objective 
 
To assess the effectiveness of intraoperative PINPOINT in identification of LNs in subjects with 
uterine and cervical malignancies who are undergoing LN mapping. 
 
10.2 Hypotheses 
 
To assess the effectiveness of PINPOINT in the identification of LNs, a non-inferiority test will 
be performed using the per-protocol (PP) analysis population. 
 
H01: 
pt  ≤ pc – 0.05 
H11: 
pt  > pc  – 0.05 
 
Here pt and pc represent the effectiveness of LN mapping with PINPOINT and Blue dye 
respectively. We define the numerator for pt as the number of nodes identified with PINPOINT 
(classifications 1, 3, 5, 7 as defined in section 8.3.1.5) and confirmed as lymphoid tissue, and we 
define the numerator for pc as the number of nodes identified with Blue dye (classifications 2, 3, 6, 7 
as defined in section 8.3.1.5) and confirmed as lymphoid tissue. We define the denominator for both 
pt and pc as the number of nodes identified by ANY method (classifications 1-7 as defined in section 
8.3.1.5). The denominator will include excised nodes confirmed as lymphoid tissue.   
 
A non-inferiority margin of 0.05 was determined to be clinically significant based on feedback 
from Investigators. Within their respective groups, pt and pc represent the proportion of LNs 
identified (and confirmed to be lymphoid tissue, See Section 8.5) with PINPOINT and Blue dye 
respectively divided by the total number of LNs identified and excised, across all subjects. 
  
We will repeat the analysis described above using the as-treated (AT) analysis set as a 
supporting analysis of the primary outcome. 
 
As a sensitivity analysis we will also perform the non-inferiority test using the mITT analysis set. 
We will also perform sensitivity analyses of the primary endpoint using a best-case and a worst-
case scenario. The best-case scenario will consider nodes with missing histology to be lymphoid 
tissue for PINPOINT and non-lymphoid tissue for Blue dye. The worst case scenario will 
consider nodes with missing histology to be non-lymphoid tissue for PINPOINT and lymphoid 
tissue for Blue dye. 
 
 
10.3 Statistical Analysis 
 
We will use the ZO statistic described by Nam and Kwon () in formulae (6) to derive the estimates 
of pt, pc, and the variance of the difference between these estimates to construct the 95% 2-
sided confidence interval for pt – pc as: 
 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 44 of 56 
Novadaq - CONFIDENTIAL 
 
 
We will perform this analysis using the PP analysis set to test the inferiority hypothesis (H01) 
stated above, and if the lower bound of the interval is > -0.05 we will claim non-inferiority. If and 
only if we reject the null (H01) hypothesis of inferiority and claim non-inferiority we will use the 
mITT analysis set to test the null (H02) stated below, and if the lower bound of the interval is 
> 0 we will claim superiority. 
 
H02: 
pt  = pc 
H12: 
pt  > pc 
 
We will repeat the analysis described above using the as-treated (AT) analysis set as a 
supporting analysis of the primary outcome. 
 
As a sensitivity analysis we will also perform the non-inferiority test using the mITT analysis set. 
We will also perform sensitivity analyses of the primary endpoint using a best-case and a worst-
case scenario. The best-case scenario will consider nodes with missing histology to be lymphoid 
tissue for PINPOINT and non-lymphoid tissue for Blue dye. The worst case scenario will consider 
nodes with missing histology to be non-lymphoid tissue for PINPOINT and lymphoid tissue for 
Blue dye. 
 
 
10.4 Sample Size Considerations 
 
The clinical literature provides an estimate of the expected effectiveness of LN mapping with ICG 
and Blue Dye17–28,36. 12 studies using ICG for the purposes of LN mapping have been 
published17–28 (Table 1). Detection rates for LN mapping with ICG and Blue dye are reported to 
occur in a wide range (33-100% for ICG17–28 and 40-80% for Blue dye36). A number of factors 
play a role in the identification of LN including tumor size, familiarity with LN mapping technique 
(learning curve) and obesity36. 
 
A weighted average of published LN detection rates for Blue dye and ICG (i.e., PINPOINT) in 
gynecological cancer suggests unilateral detection rates of 91% for ICG and 80% for Blue dye. 
However, we assumed LN detection rates in gynecological cancer17–28 of 84% and 80% using 
ICG and Blue dye, respectively. We used a lower LN detection rate of 84% for ICG and a LN 
detection rate at the upper end of the range for Blue dye as a conservative approach to the 
sample size calculation. We also assumed a non-inferiority margin of  5%. 
 
The power calculation was performed for a 2-level hierarchical model in which nodes are nested 
within subject. Power was calculated as a function of the effective sample size (ESS), which is 
a function of the total number of nodes excised, the number of nodes within subjects (clusters), 
and the intra-cluster correlation (ICC). Specifically, ESS = n / VIF, where n is the total number of 
nodes excised across all patients, and VIF is the variance inflation factor, calculated as 
VIF = 1 + (m - 1) × ICC, where m is the number of nodes per subject. Because we expect to 
excise 3 to 4 nodes per subject, with 150 subjects we expect to excise 3.5 × 150 = 525 nodes. 
With 3.5 nodes per subject on average and an ICC at most 0.125 we will have VIF at most 1 + 
(2 × 3.5 – 1) × 0.125 = 1.75 and an ESS at least 525 / 1.75 = 300 nodes. Note that here m is 
twice the number of expected nodes per subject, since nodes will be identified using 2 different 
methods within the same subject. We expect the ICC to be at most 0.125 based on our estimate 
of the ICC =  0.07 from Crane et al.
18. 
 
With an ESS of at least 300 Ns we will have at least 82% power to reject H01 above and claim 
non-inferiority of PINPOINT with respect to Blue dye. This sample size calculation was 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 45 of 56 
Novadaq - CONFIDENTIAL 
 
 
performed using nQuery Advisor ® 7.0 (Copyright © 1995-2007, Statistical Solutions, Saugus, 
MA). We will test the hypothesis using a two-sided 95% confidence interval (i.e., two-sided 
significance level of 0.05). We will enroll subjects and identify Ns using both Blue dye and 
PINPOINT as described above in section 8.3.1.5 until we have at least 525 LNs identified, 
regardless of the method used to identify them. We expect that we will enroll approximately 150 
subjects to obtain 525 nodes (based on clinical literature suggesting an average of 3-4 Ns 
excised per subject17–28). 
 
10.5 Data Sets to be Analyzed 
10.5.1 Per-protocol (PP) 
 
The Per-Protocol (PP) analysis population includes all subjects that: [1] meet critical eligibility 
criteria, [2] have no significant protocol deviations; and [3] have evaluable assessment 
endpoints for the primary endpoint. 
We believe that the PP population will be the population that will most likely demonstrate a 
difference between Blue dye and IC2000 with respect to their ability to identify lymph nodes, 
should a difference exist. Thus, since we are trying to show non-inferiority of IC2000 with respect 
to Blue dye, we believe that using the PP population for testing non-inferiority is the conservative 
approach 
10.5.2 Modified Intent to treat (mITT) 
 
The mITT analysis population includes all randomized subjects who received at least one 
injection of IC2000 or Blue dye. All subjects meeting this criterion are included in the mITT 
population regardless of whether or not they received the minimally invasive surgical 
intervention or lymphatic mapping. Subjects who have the mapping procedure aborted due to 
circumstances such as a higher stage cancer than initially expected will not be included in the 
mITT. Approximately 8% of subjects are expected to have the mapping procedure aborted. 
 
We believe the mITT population will be the population that will most likely demonstrate no 
difference between the Blue dye and IC2000 with respect to their ability to identify lymph nodes, 
because the mITT population includes subjects who may not have received the full dose of dye, 
and it includes subjects who may have not received lymphatic mapping, but who may have had 
lymph nodes identified by gross inspection. Thus, we believe that using the mITT population for 
testing superiority will be the conservative approach. 
 
10.5.3 As-Treated (AT) 
 
The As-Treated (AT) analysis population includes all randomized subjects in whom the intended 
minimally invasive surgical procedure was performed and received at least one injection of 
IC2000 or Blue dye. Subjects in whom the mapping procedure with PINPOINT or Blue dye is not 
performed are excluded from the AT population. Subjects will be analyzed according to the LN 
mapping procedure performed. The AT population will be used for a secondary analysis of the 
primary endpoint. 
 
10.5.4 Safety (S) 
 
The safety analysis population includes all randomized subjects enrolled in the study who 
received at least one injection of IC2000 or Blue dye. Secondary safety endpoints, including the 
summary of adverse events or adverse device effects in the trial, will be analyzed using this 
analysis population. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 46 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
10.6 Secondary Objectives 
 
The planned secondary out comes are intended to support product labelling. We will use the 
step-down method described by Benjamini and Liu37 to control the false discovery rate at 0.05 
(2-sided) while testing our secondary objectives. 
 
The first secondary outcome is the ability of PINPOINT and Blue dye to detect at least one lymph 
node in a subject. 
 
Let qt and qc represent the proportion of subjects with a least one lymph node identified 
(according to section 8.3.1.5 and confirmed by histology) with PINPOINT and Blue dye 
respectively, divided by the total number of subjects where mapping was attempted. That is, the 
numerator for qt is the number of subjects with at least 1 node identified with PINPOINT 
(classifications 1, 3, 5, 7) and confirmed as lymphoid tissue, and the numerator for qc is the 
number of subjects with at least 1 node identified with Blue dye (classifications 2, 3, 6, 7) and 
confirmed as lymphoid tissue. The denominator of both qt and qc is the number of subjects where 
mapping was attempted. 
The following hypotheses will be tested: 
 
 
H03: qt ≤ qc – 0.05 
H13:  qt  > qc – 0.05 
 
To test this hypothesis we will estimate the difference qt – qc with a 95% two-sided confidence 
interval. We will perform this analysis using the PP analysis set to test the inferiority hypothesis 
(H03) stated above, and if the lower bound of the interval is greater than -0.05 we will claim non-
inferiority. If and only if we reject the inferiority hypothesis (H03) we will use the mITT analysis set 
to test for superiority, and if the lower bound of the interval is greater than 0 we will claim 
superiority. 
 
Another secondary outcome is the bilateral LN detection rate. Let bt and bc represent the 
proportion of subjects with at least one node identified on the right side and on the left side of 
the pelvis and confirmed as lymphoid tissue with PINPOINT and Blue dye, respectively. That is, 
the numerator for bt is the number of subjects with at least 1 node identified with PINPOINT () on 
the right side of the pelvis and confirmed as lymphoid tissue and at least 1 node identified with 
PINPOINT on the left side of the pelvis and confirmed as lymphoid tissue. Similarly, the numerator 
for bc is the number of subjects with at least 1 node identified with Blue dye (classifications 2, 3, 
6, 7) on the right side of the pelvis and confirmed as lymphoid tissue and at least 1 node identified 
with Blue dye on the left side of the pelvis and confirmed as lymphoid tissue. The denominator of 
both bt and bc is the number of subjects where mapping was attempted. 
 
The following hypotheses will be tested: 
H04:  bt ≤ bc – 0.05 
H14:  bt  > bc – 0.05 
 
To test this hypothesis we will estimate the difference bt – bc with a 95% two-sided confidence 
interval.  We will perform this analysis using the PP analysis set to test the inferiority hypothesis 
(H04) stated above, and if the lower bound of the interval is greater than -0.05 we will claim non-
inferiority.  If and only if we reject the inferiority hypothesis (H04) we will use the mITT analysis 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 47 of 56 
Novadaq - CONFIDENTIAL 
 
 
set to test for superiority, and if the lower bound of the interval is greater than 0 we will claim 
superiority. 
 
A third secondary outcome is the proportion of LNs identified by following lymphatic channels 
(ducts). Let dt and dc represent the proportion of nodes identified by following a duct and 
confirmed as lymphoid tissue with PINPOINT and Blue dye, respectively. That is, the numerator 
for dt is the number of nodes identified with PINPOINT by following a duct (classifications 5, 7) 
and confirmed as lymphoid tissue. Similarly, the numerator for dc is the number nodes identified 
with Blue dye by following a duct (classifications 6, 7) and confirmed as lymphoid tissue. We 
define the denominator for both dt and dc as the number of nodes identified by ANY method 
(classifications 1-7). The denominator will include excised nodes confirmed as lymphoid tissue. 
 
The following hypotheses will be tested: 
H05: dt ≤ dc – 0.05 
H15:  dt  > dc – 0.05 
 
To test this hypothesis we will estimate the difference dt – dc with a 95% two-sided confidence 
interval. We will estimate this confidence interval in a manner similar to that described for the 
primary outcome. We will perform this analysis using the PP analysis set to test the inferiority 
hypothesis (H05) stated above, and if the lower bound of the interval is greater than -0.05 we will 
claim non-inferiority. If and only if we reject the inferiority hypothesis (H05) we will use the mITT 
analysis set to test for superiority, and if the lower bound of the interval is greater than 0 we will 
claim superiority. 
 
We will also tabulate the anatomic distribution of LNs identified by each dye. 
 
10.6.1 Demographic and Baseline Data 
 
The demographic and baseline analysis will be done for the mITT and PP data set. 
 
The following subject variables will be summarized: age, race, body mass index, histological 
type (squamous cell carcinoma, adenocarcinoma, endometrioid carcinoma etc.), previous 
neoadjuvant therapy, FIGO stage and type of surgical intervention. Continuous variables will be 
summarized as mean, standard deviation, median, minimum and maximum, and categorical 
variables will be summarized by counts and percentages. 
 
10.6.2 Safety Variables and Analysis 
 
Safety variables will be documented and summarized for all randomized subjects enrolled in the 
study who received at least one injection of IC2000 or Blue dye. Safety variables will include all 
adverse events (AEs) and adverse device effects (ADEs), concomitant medications, and vital 
signs. Safety analysis will be performed on all subjects who receive IC2000 regardless of whether 
LN mapping was initiated or successful. 
 
Adverse events will be coded using the National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE). Treatment-emergent AEs and ADEs will be summarized 
descriptively. The number and percentage of subjects experiencing AEs and ADEs and the total 
number  of  AEs  and  ADEs  will  be  summarized  by system  organ  class and preferred term. 
Associated AEs that investigators suspect are related to study treatment will also be 
summarized. Summary of each type of event will be prepared by severity and for all severities 
combined. 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 48 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
10.7 Handling of Missing Data 
 
Reasonable efforts will be made to obtain complete data for all subjects; however, missing 
observations will inevitably occur due to subjects lost to follow-up or noncompliance with 
required assessments. The reasons for missing data will be documented and evaluated (e.g. 
subject is deceased, lost to follow up, missed visit, etc.). In addition, the distribution of prognostic 
factors between subjects with data and those without data will be examined to evaluate any 
potential sources of bias. Any missing observations will be described in detail and evaluated for 
assessment of possible bias. 
A sensitivity analyses of the primary and secondary endpoints will be conducted using a best- 
case and a worst-case scenario. The best-case scenario will consider nodes with missing 
histology as lymphoid tissue for PINPOINT and as non-lymphoid tissue for Blue dye. The worst- 
case scenario will consider nodes with missing histology as non-lymphoid tissue for PINPOINT 
and as lymphoid tissue for Blue dye. 
 
 
10.8 Pooling of Site Data 
 
The homogeneity of safety and effectiveness results across study sites will be examined and if 
no significant heterogeneity is found, the results will be pooled. The justification for pooling is 
that all study sites will follow one Protocol, use the same device system (PINPOINT) follow the 
same Instructions for Use and perform mapping in accordance with NCCN guidelines. 
Additionally, frequent contact and monitoring of the sites will be performed to ensure that all 
Study sites are evaluating participants and recording Study results in a reliable and reproducible 
manner. It is not anticipated that any individual Study site will dominate the Study results. 
Therefore, it is believed that these procedures will help to ensure that the data from these Study 
sites can be combined and analyzed as if generated at a single site. 
 
11 ESTIMATED DURATION OF THE STUDY 
 
The expected study duration is approximately 1 year. The study is expected to start in 2015 and 
take 18 months to complete enrollment. 
 
12 STUDY ETHICAL CONSIDERATIONS 
 
12.1 Ethical Conduct of the Study 
 
The study will be conducted in accordance with US 21 CFR Parts 50, 54, 56, 312 and 812 as 
well as ICH E6: Good Clinical Practice: Consolidated Guideline. It will be constituted in keeping 
with the principles of ICH E8: General Considerations for Clinical Trials and Part C, Division 5 
of the Canadian Food and Drug Regulations. Any additional requirements imposed by the local 
Institutional Review Board/Ethics Committee/Research Ethics Board or regulatory agency will 
be followed as necessary. 
 
12.2 Informed Consent 
 
The informed consent forms used for the study must comply with applicable laws and regulations. 
An Investigator must explain the medical aspects of the study, including the nature of the study 
and procedure, orally and in writing, in such a manner that the subject is aware of potential 
benefits and risks. Other elements of the informed consent process may be delegated by the 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 49 of 56 
Novadaq - CONFIDENTIAL 
 
 
Investigator. Subjects must be informed about all aspects of the clinical study that are necessary 
to make the decision to participate in the clinical trial. Subjects must be informed that participation 
is voluntary and that they may withdraw from the study at any time, without prejudice. 
Documentation of the discussion and the date of informed consent must be recorded in the source 
documentation. Subjects must give informed consent in writing. 
 
The informed consent process must be conducted, and the form must be signed, before the 
subject undergoes any screening procedures that are performed solely for the purpose of 
determining eligibility for the study. 
 
12.3 Institutional Review Board, Ethics Committee, or Research Ethics Board (IRB) 
 
The protocol, protocol amendments (as specified by the IRB), and the informed consent form for 
the proposed study, along with any other documents required by the center's IRB must be 
submitted by the Investigator to the center's duly constituted IRB for review and approval. The 
Investigator must also ensure that the IRB reviews the progress of the study on a regular basis 
and, if necessary, renews its approval of the study on an annual basis. A copy of each IRB 
approval letter must be forwarded to the Sponsor before the study is implemented. 
Documentation of subsequent reviews of the study must also be forwarded to the Sponsor. 
 
12.4 Data and Safety Monitoring Board 
 
The study will be reviewed annually by an independent Data and Safety Monitoring Board 
(DSMB). The independent statistician will prepare a report for the DSMB in advance of the 
scheduled review meeting using the report template provided by the DSMB. The independent 
statistician will also prepare a safety report for the study Principal Investigator (PI) in preparation 
of the DSMB meeting to review the study. A DSMB charter will outline specific safety and data 
monitoring procedures. 
 
13 ADMINISTRATIVE PROCEDURES 
 
13.1 Sponsor's Responsibilities 
 
13.1.1 Public Disclosure of Clinical Trials 
 
The Sponsor will submit information about this protocol to the appropriate web-based national 
clinical trial registry and results database in each applicable regulatory region where the study is 
conducted. This includes but is not limited to US National Institute of Health 
(www.clinicaltrials.gov). 
 
13.1.2 Study Supplies 
 
The Sponsor will provide the PINPOINT Endoscopic Fluorescence Imaging System along with 
sufficient quantities of PINPOINT LN Mapping Kits and sufficient quantities of Blue dye 
(Isosulfan blue). 
 
13.1.3 Investigator Training 
 
13.1.3.1 Study Initiation Visit 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 50 of 56 
Novadaq - CONFIDENTIAL 
 
 
Study centers will have a study initiation meeting to ensure the research personnel understand 
the protocol, study requirements, and data capture processes. This training will take place prior 
to enrollment of the first subject at each study center. 
 
13.1.3.2 PINPOINT System 
 
Appropriate personnel at the study centers shall be required to participate in training on the 
procedural use of PINPOINT as it relates to the conduct of this study (refer to Section 6.2.3). 
 
13.1.4 Ongoing Communication of Safety Information During the Study 
 
The Sponsor will provide the Investigator with documentation of UADEs and reportable 
events/effects, from all study centers, reported to regulatory authorities during the conduct of 
the study. The Investigator must forward this documentation to the IRB, as described in Section 
9. 
 
The Sponsor will also notify the Investigator about any other safety findings that could affect the 
safety of subjects, affect the conduct of the study, or alter the IRB's opinion about continuation 
of the study. 
 
13.1.5 Study Monitoring 
 
The conduct of the study will be monitored by representatives of the Sponsor to ensure 
compliance with the protocol, GCP and applicable regulations. A separate study specific 
Monitoring Plan will outline the monitoring procedures to be followed, the required access to 
source data and the extent of source verification planned. 
 
13.1.6 Records Retention 
 
The Sponsor must retain all documentation pertaining to the study according to Novadaq 
standard operating procedures. 
 
13.2 Investigator's Responsibilities 
 
13.2.1 Reporting and Recording of Study Data 
 
Data will be captured and compiled using procedures developed by the Sponsor or their 
representatives. All requested study data must be recorded clearly on the CRF and other study 
forms as required. An explanation should be provided for all missing data. Only individuals who 
are identified on the Study Signature and Delegation Log may enter or correct data in the CRF. 
Incomplete or inconsistent data on the CRFs will result in data queries that require resolution by 
the Investigator. 
 
The protocol, informed consent form, protocol amendments, safety information, and other 
required documents must be submitted to the IRB in a timely manner, as described in Section 
12.3. 
 
13.2.2 Source Documentation 
 
The Investigator must maintain adequate and accurate source documents upon which CRFs for 
each subject are based. They are to be separate and distinct from CRFs, except for cases in 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 51 of 56 
Novadaq - CONFIDENTIAL 
 
 
which the Sponsor has predetermined that direct data entry into specified pages of the subject's 
CRF is appropriate. These records should include detailed notes on: 
 
 
The oral and written communication with the subject regarding the study treatment 
(including the risks and benefits of the study). The date of informed consent must be 
recorded in the source documentation. 
 
The subject's basic identifying information, such as demographics, that links the subject's 
source documents with the CRFs. 
 
All relevant observations and data on the condition of the subject throughout the study. 
 
The subject's exposure to PINPOINT. 
 
All adverse events. 
 
13.2.3 Study Devices and Imaging Agents 
 
The Investigator is responsible for ensuring the PINPOINT system, including imaging agent, and 
Blue dye are controlled and are used or dispensed only to subjects enrolled in the study. Only 
Investigators identified on the Signature and Delegation Log may use PINPOINT for the 
purposes of this study. 
 
The Investigator shall keep records documenting the receipt, use, return and disposal of the 
study device, drugs and components. 
 
The Investigator will ensure that PINPOINT is returned and that any other study material will be 
returned to the Sponsor or disposed of according to the Sponsor’s instructions on completion of 
the study. 
 
13.2.4 Records Retention 
 
The Investigator must ensure that clinical study records are retained according to national 
regulations, as documented in the clinical trial agreement entered into with the Sponsor in 
connection with this study. 
 
Subject files and other source data must be kept for the maximum period of time permitted by 
the hospital, institution, or private practice. The Investigator must inform the Sponsor 
immediately if any documents are to be destroyed, to be transferred to a different facility, or to 
be transferred to a different owner. 
 
14 DATA MANAGEMENT 
 
Study data will be collected using paper and/or or electronic case report forms (CRFs). Data will 
be entered into a study specific database in one of two ways or a combination of the following: 
 
 
Center research personnel will enter study data directly into an electronic case report 
form which functions as an electronic data capture screen for the study database. 
 
 
Center research personnel will enter study data onto paper CRFs, which will be 
submitted to the Sponsor or assigned designee. 
 
The Sponsor or designee will follow standardized procedures for data review, database cleaning 
and issuing/resolving queries. Procedures for data verification, validation, security and data 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 52 of 56 
Novadaq - CONFIDENTIAL 
 
 
retention will be followed in order that the study data reported are complete, accurate and 
consistent with source data. 
 
For the purpose of data analysis and presentation, the data of the original data set may be 
manipulated and additional variables calculated when necessary. Once the study data are 
completely entered, reviewed and checked, the study database will be locked and no further 
changes will be made. 
 
The electronic CRFs will be created and managed using REDCap33 (Research Electronic Data 
Capture) electronic data capture tools hosted at M.D. Anderson. REDCap (www.project- 
redcap.org) is a secure, web-based application with controlled access designed to support data 
capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit 
trails for tracking data manipulation and export procedures; 3) automated export procedures for 
seamless downloads to common statistical packages; and 4) procedures for importing data from 
external sources. In the case of multi-center studies REDCap uses Data Access Groups (DAGs) 
to ensure that personnel at each institution are blinded to the data from other institutions. 
REDCap (https://redcap.mdanderson.org) is hosted on a secure server by M.D. Anderson 
Cancer Center's Department of Research Information Systems & Technology Services. 
REDCap has undergone a Governance Risk & Compliance Assessment (May 2014) by M.D. 
Anderson's Information Security Office and found to be compliant with HIPAA, Texas 
Administrative Codes 202-203, University of Texas Policy 165, federal regulations outlined in 
21CFR Part 11, and UTMDACC Institutional Policy #ADM0335. 
 
Those having access to the data include the study PI and research team personnel. Users are 
authenticated against M.D. Anderson’s Active Directory system. External collaborators are given 
access to the database once approved by the PI, with their access expiring in 6 months but 
renewable in 6 months increments at the request of the PI. The application is accessed through 
Secure Socket Layer (SSL). All protected health information (PHI) will be removed from the data 
when it is exported from REDCap for analysis. All dates for a given subject will be shifted by a 
randomly generated number between 0 and 364, thus preserving the distance between dates. 
Dates for each subject will be shifted by a different randomly generated number. 
 
Following publication study data will be archived in REDCap. Since study data may be useful for 
future research studies performed under separate IRB approved protocols, study data will be 
archived indefinitely by the sponsor. Since REDCap is a secure electronic database with 
controlled access, and because subject identifiers may be needed to link study data to data from 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 53 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
other sources under future IRB approved protocols, subject identifying information will be 
retained in the archived database. 
 
15 POLICY FOR PUBLICATION AND PRESENTATION OF DATA 
 
The results of the study will be published by the study group. In addition to the principal 
investigators, any additional authors listed separately on the manuscript will be selected based 
on scientific input on the design of the study, interpretation of results and on enrollment 
numbers. The final number of authors will depend on the journal’s publication guidelines. All 
participating centers will be acknowledged in the main study manuscript. 
 
The Sponsor also encourages the scientific publication of data from clinical research studies. 
However, Investigators may not present or publish partial or complete study results individually 
without participation of the study Principal Investigator as well as the Sponsor. The Principal 
Investigators and the Sponsor may propose appropriate scientific manuscripts or abstracts from 
the study data. All proposed publications must be reviewed and commented on by the Sponsor 
before submission for publication. The detailed procedures for the review of publications are set 
out in the clinical trial agreement entered into with the Sponsor in connection with this study. 
These procedures are in place to ensure coordination of study data publication and adequate 
review of data for publication against the validated study database for accuracy. Names of all 
Investigators and Sponsor representatives responsible for designing the study and analyzing 
the results will be included in the publication(s). 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 54 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
16 REFERENCES 
 
1. 
The National Comprehensive Cancer Network. Uterine Neoplasms. (2015). 
 
2. 
The National Comprehensive Cancer Network. Cervical Neoplasms. (2015). 
 
3. 
Nam J-M and Kwon D. Non-inferiority tests for clustered matched-pair data. Statistics in 
Medicine. 28, 1668-1679 (2009). 
 
4. 
Abu-Rustum, N. R. Sentinel lymph node mapping for endometrial cancer: a modern 
approach to surgical staging. J. Natl. Compr. Canc. Netw. 12, 288–97 (2014). 
 
5. 
Sentinel Lymph Node Biopsy - National Cancer Institute. at 
<http://www.cancer.gov/cancertopics/factsheet/detection/sentinel-node-biopsy> 
 
6. 
Chen, S. L., Iddings, D. M., Scheri, R. P. & Bilchik, A. J. Lymphatic Mapping and Sentinel 
Node Analysis: Current Concepts and Applications. CA. Cancer J. Clin. 56, 292–309 
(2006). 
 
7. 
Xiong, L. et al. Indocyanine green fluorescence-guided sentinel node biopsy: A meta- 
analysis on detection rate and diagnostic performance. Eur. J. Surg. Oncol. 40, 843–9 
(2014). 
 
8. 
Kamisaka, K., Yatsuji, Y., Yamada, H. & Kameda, H. The binding of indocyanine green 
and other organic anions to serum proteins in liver diseases. Clin. Chim. Acta. 53, 255– 
64 (1974). 
 
9. 
Marshall, M. V et al. Near-Infrared Fluorescence Imaging in Humans with Indocyanine 
Green: A Review and Update. Open Surg. Oncol. J. 2, 12–25 (2010). 
 
10. 
What are the key statistics about endometrial cancer? at 
<http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine- 
cancer-key-statistics> 
 
11. 
Canadian Cancer Statistics publication - Canadian Cancer Society. at 
<http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics- 
publication/?region=pe> 
 
12. 
What are the key statistics about cervical cancer? at 
<http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key- 
statistics> 
 
13. 
Koh, W.-J. et al. Uterine Neoplasms, Version 1.2014. J Natl Compr Canc Netw 12, 248– 
280 (2014). 
 
14. 
IC-GREEN (indocyanine green for injection, USP). (2012). 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 55 of 56 
Novadaq - CONFIDENTIAL 
 
 
 
15. 
ICG-Pulsion (25mg/50mg powder for solution for injection) prescribing information. 
 
16. 
PINPOINT Operator ’s Manual. (USA. Rev B 2016, Rev.A, 2016). 
 
17. 
Furukawa, N. et al. The usefulness of photodynamic eye for sentinel lymph 
node identification in patients with cervical cancer. Tumori 96, 936–40 (2010). 
 
18. 
Crane, L. M. A. et al. Intraoperative near-infrared fluorescence imaging for sentinel 
lymph node detection in vulvar cancer: first clinical results. Gynecol. Oncol. 120, 291–5 
(2011). 
 
19. 
Crane, L. M. a et al. Intraoperative multispectral fluorescence imaging for the detection 
of the sentinel lymph node in cervical cancer: a novel concept. Mol. Imaging Biol. 13, 
1043– 9 (2011). 
 
20. 
Holloway, R. W. et al. Detection of sentinel lymph nodes in patients with 
endometrial cancer undergoing robotic-assisted staging: a comparison of 
colorimetric and fluorescence imaging. Gynecol. Oncol. 126, 25–9 (2012). 
 
21. 
Rossi, E. C., Ivanova, A. & Boggess, J. F. Robotically assisted fluorescence-guided 
lymph node mapping with ICG for gynecologic malignancies: a feasibility study. 
Gynecol. Oncol. 124, 78–82 (2012). 
 
22. 
Schaafsma, B. E. et al. Randomized comparison of near-infrared fluorescence lymphatic 
tracers for sentinel lymph node mapping of cervical cancer. Gynecol. Oncol. 127, 126–
30 (2012). 
 
23. 
Rossi, E. C., Jackson, A., Ivanova, A. & Boggess, J. F. Detection of sentinel nodes 
for endometrial cancer with robotic assisted fluorescence imaging: cervical versus 
hysteroscopic injection. Int. J. Gynecol. Cancer 23, 1704–11 (2013). 
 
24. 
Schaafsma, B. E. et al. Near-infrared fluorescence sentinel lymph node biopsy in 
vulvar cancer: a randomised comparison of lymphatic tracers. BJOG 120, 758–64 
(2013). 
 
25. 
Jewell, E. L. et al. Detection of sentinel lymph nodes in minimally invasive surgery 
using indocyanine green and near-infrared fluorescence imaging for uterine and 
cervical malignancies. Gynecol. Oncol. 133, 274–7 (2014). 
 
26. 
Sinno, A. K., Fader, A. N., Roche, K. L., Giuntoli, R. L. & Tanner, E. J. A Comparison 
of Colorimetric versus Fluorometric Sentinel Lymph Node Mapping During Robotic 
Surgery for Endometrial Cancer. Gynecol. Oncol. (2014). 
doi:10.1016/j.ygyno.2014.05.022 
 
27. 
Plante, M. et al. Sentinel node mapping with indocyanine green and endoscopic 
near- infrared fluorescence imaging in endometrial cancer. A pilot study and review 
of the literature. Gynecol. Oncol. (2015). doi:10.1016/j.ygyno.2015.03.004 
 

PINPOINT® for Lymph Node Mapping 
Clinical Study Protocol PP LNM 01 
Version 6.0, August 25th, 2017 
Page 56 of 56 
Novadaq - CONFIDENTIAL 
 
 
28. 
How, J. et al. Comparing indocyanine green, technetium, and blue dye for sentinel 
lymph node mapping in endometrial cancer. Gynecol. Oncol. (2015). 
doi:10.1016/j.ygyno.2015.04.004 
 
29. 
Proulx, S. T. et al. Quantitative imaging of lymphatic function with liposomal indocyanine 
green. Cancer Res. 70, 7053–62 (2010). 
 
30. 
Rosenthal, E. L., Warram, J. M., Bland, K. I. & Zinn, K. R. The status of contemporary 
image-guided modalities in oncologic surgery. Ann. Surg. 261, 46–55 (2015). 
 
31. 
Heuveling, D. A. et al. Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent 
tracer with optimal retention in the sentinel lymph node. Eur. J. Nucl. Med. Mol. Imaging 
39, 1161–8 (2012). 
 
32. 
Chi, C. et al. Use of indocyanine green for detecting the sentinel lymph node in breast 
cancer patients: from preclinical evaluation to clinical validation. PLoS One 8, e83927 
(2013). 
 
33. 
Mylan Institutional LLC. ISOSULFAN BLUE- HIGHLIGHTS OF PRESCRIBING 
INFORMATION. (2013). 
 
34. 
Kim, C. H. et al. Pathologic ultrastaging improves micrometastasis detection in sentinel 
lymph nodes during endometrial cancer staging. Int. J. Gynecol. Cancer 23, 964–70 
(2013) 
 
35. 
Lesaffre, E. Use and misuse of the p-value. Bull. NYU Hosp. Jt. Dis. 66, 146–9 (2008). 
 
36. 
Kadkhodayan, S. et al. Sentinel node biopsy for lymph nodal staging of uterine cervix 
cancer: A systematic review and meta-analysis of the pertinent literature. Eur. J. Surg. 
Oncol. 41, 1–20 (2015).